UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark One)
þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2015 | ||
OR | ||
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
FOR THE TRANSITION PERIOD FROM TO |
COMMISSION FILE NUMBER: 814-00802
HORIZON TECHNOLOGY FINANCE CORPORATION
(Exact name of registrant as specified in its charter)
DELAWARE | 27-2114934 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
312 Farmington Avenue | |
Farmington, CT | 06032 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including
area code (860) 676-8654
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨.
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer” and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer ¨ | Accelerated filer þ | Non-accelerated filer ¨ | Smaller Reporting Company ¨ | |||
(Do not check if a smaller reporting company) |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ.
As of May 5, 2015, the Registrant had 11,631,494 shares of common stock, $0.001 par value, outstanding.
HORIZON TECHNOLOGY FINANCE CORPORATION
FORM 10-Q
TABLE OF CONTENTS
2 |
Item 1. Consolidated Financial Statements
Horizon Technology Finance Corporation and Subsidiaries
Consolidated Statements of Assets and Liabilities (Unaudited)
(In thousands, except share and per share data)
March 31, 2015 | December 31, 2014 | |||||||
Assets | ||||||||
Non-affiliate investments at fair value (cost of $207,905 and $209,838, respectively) (Note 4) | $ | 204,300 | $ | 205,101 | ||||
Investment in money market funds | 399 | 27 | ||||||
Cash | 29,828 | 8,417 | ||||||
Restricted investments in money market funds | 2,351 | 2,906 | ||||||
Interest receivable | 5,057 | 4,758 | ||||||
Other assets | 3,497 | 3,987 | ||||||
Total assets | $ | 245,432 | $ | 225,196 | ||||
Liabilities | ||||||||
Borrowings (Note 6) | $ | 74,342 | $ | 81,753 | ||||
Distribution payable | 3,783 | 3,322 | ||||||
Base management fee payable (Note 3) | 354 | 356 | ||||||
Incentive fee payable (Note 3) | 736 | 799 | ||||||
Other accrued expenses | 1,204 | 718 | ||||||
Total liabilities | 80,419 | 86,948 | ||||||
Commitments and Contingencies (Notes 7 and 8) | ||||||||
Net assets | ||||||||
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2015 and December 31, 2014 | — | — | ||||||
Common stock, par value $0.001 per share, 100,000,000 shares authorized, 11,630,617 and 9,628,124 shares outstanding as of March 31, 2015 and December 31, 2014, respectively | 12 | 10 | ||||||
Paid-in capital in excess of par | 180,970 | 155,240 | ||||||
Distributions in excess of net investment income | (1,049 | ) | (1,102 | ) | ||||
Net unrealized depreciation on investments | (3,605 | ) | (4,737 | ) | ||||
Net realized loss on investments | (11,315 | ) | (11,163 | ) | ||||
Total net assets | 165,013 | 138,248 | ||||||
Total liabilities and net assets | $ | 245,432 | $ | 225,196 | ||||
Net asset value per common share | $ | 14.19 | $ | 14.36 |
See Notes to Consolidated Financial Statements
3 |
Horizon Technology Finance Corporation and Subsidiaries
Consolidated Statements of Operations (Unaudited)
(In thousands, except share and per share data)
For the Three Months Ended | ||||||||
March 31, | ||||||||
2015 | 2014 | |||||||
Investment income | ||||||||
Interest income on non-affiliate investments | $ | 6,562 | $ | 7,180 | ||||
Prepayment fee income on non-affiliate investments | 520 | — | ||||||
Fee income on non-affiliate investments | 184 | 354 | ||||||
Total investment income | 7,266 | 7,534 | ||||||
Expenses | ||||||||
Interest expense | 1,587 | 2,070 | ||||||
Base management fee (Note 3) | 1,031 | 1,312 | ||||||
Performance based incentive fee (Note 3) | 736 | 513 | ||||||
Administrative fee (Note 3) | 268 | 244 | ||||||
Professional fees | 431 | 835 | ||||||
General and administrative | 260 | 250 | ||||||
Total expenses | 4,313 | 5,224 | ||||||
Management and performance based incentive fees waived (Note 3) | — | (214 | ) | |||||
Net expenses | 4,313 | 5,010 | ||||||
Net investment income before excise tax | 2,953 | 2,524 | ||||||
Provision for excise tax | (10 | ) | (40 | ) | ||||
Net investment income | 2,943 | 2,484 | ||||||
Net realized and unrealized (loss) gain on investments | ||||||||
Net realized loss on investments | (230 | ) | (5,884 | ) | ||||
Net unrealized appreciation on investments | 1,132 | 8,530 | ||||||
Net realized and unrealized gain on investments | 902 | 2,646 | ||||||
Net increase in net assets resulting from operations | $ | 3,845 | $ | 5,130 | ||||
Net investment income per common share | $ | 0.30 | $ | 0.26 | ||||
Net increase in net assets per common share | $ | 0.39 | $ | 0.53 | ||||
Distributions declared per share | $ | 0.345 | $ | 0.345 | ||||
Weighted average shares outstanding | 9,807,198 | 9,613,829 |
See Notes to Consolidated Financial Statements
4 |
Horizon Technology Finance Corporation and Subsidiaries
Consolidated Statements of Changes in Net Assets (Unaudited)
(In thousands, except share data)
Common Stock | Paid-In Capital in Excess of | Accumulated Undistributed (distributions in excess of) Net Investment | Net
Unrealized (Depreciation) Appreciation on | Net
Realized Gain (Loss) on | Total Net | |||||||||||||||||||||||
Shares | Amount | Par | Income | Investments | Investments | Assets | ||||||||||||||||||||||
Balance at December 31, 2013 | 9,608,949 | $ | 10 | $ | 154,975 | $ | 1,463 | $ | (13,026 | ) | $ | (7,587 | ) | $ | 135,835 | |||||||||||||
Net increase in net assets resulting from operations | — | — | — | 2,484 | 8,530 | (5,884 | ) | 5,130 | ||||||||||||||||||||
Issuance of common stock under dividend reinvestment plan | 9,741 | — | 133 | — | — | — | 133 | |||||||||||||||||||||
Distributions declared | — | — | — | (3,318 | ) | — | — | (3,318 | ) | |||||||||||||||||||
Balance at March 31, 2014 | 9,618,690 | $ | 10 | $ | 155,108 | $ | 629 | $ | (4,496 | ) | $ | (13,471 | ) | $ | 137,780 | |||||||||||||
Balance at December 31, 2014 | 9,628,124 | $ | 10 | $ | 155,240 | $ | (1,102 | ) | $ | (4,737 | ) | $ | (11,163 | ) | $ | 138,248 | ||||||||||||
Issuance of common stock, net of offering costs | 2,000,000 | 2 | 26,667 | — | — | — | 26,669 | |||||||||||||||||||||
Net increase in net assets resulting from operations | — | — | — | 2,943 | 1,132 | (230 | ) | 3,845 | ||||||||||||||||||||
Issuance of common stock under dividend reinvestment plan | 2,493 | — | 34 | — | — | — | 34 | |||||||||||||||||||||
Distributions declared | — | — | — | (3,783 | ) | — | — | (3,783 | ) | |||||||||||||||||||
Reclassification of permanent tax differences (Note 2) | — | — | (971 | ) | 893 | — | 78 | — | ||||||||||||||||||||
Balance at March 31, 2015 | 11,630,617 | $ | 12 | $ | 180,970 | $ | (1,049 | ) | $ | (3,605 | ) | $ | (11,315 | ) | $ | 165,013 |
See Notes to Consolidated Financial Statements
5 |
Horizon Technology Finance Corporation and Subsidiaries
Consolidated Statements of Cash Flows (Unaudited)
(In thousands)
For the Three Months Ended | ||||||||
March 31, | ||||||||
2015 | 2014 | |||||||
Cash flows from operating activities: | ||||||||
Net increase in net assets resulting from operations | $ | 3,845 | $ | 5,130 | ||||
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities: | ||||||||
Amortization of debt issuance costs | 278 | 492 | ||||||
Net realized loss on investments | 230 | 6,913 | ||||||
Net unrealized appreciation on investments | (1,132 | ) | (8,530 | ) | ||||
Purchase of investments | (23,933 | ) | (17,926 | ) | ||||
Principal payments received on investments | 25,790 | 11,773 | ||||||
Proceeds from sale of investments | — | 720 | ||||||
Changes in assets and liabilities: | ||||||||
Net increase in investments in money market funds | (372 | ) | (913 | ) | ||||
Net decrease in restricted investments in money market funds | 555 | 221 | ||||||
Decrease (increase) in interest receivable | 71 | (597 | ) | |||||
Increase in end-of-term payments | (370 | ) | (552 | ) | ||||
Decrease in unearned income | (154 | ) | (226 | ) | ||||
Decrease (increase) in other assets | 212 | (1,129 | ) | |||||
Increase (decrease) in other accrued expenses | 486 | (50 | ) | |||||
Decrease in base management fee payable | (2 | ) | (109 | ) | ||||
Decrease in incentive fee payable | (63 | ) | (446 | ) | ||||
Net cash provided by (used in) operating activities | 5,441 | (5,229 | ) | |||||
Cash flows from financing activities: | ||||||||
Proceeds from issuance of common stock, net of offering costs | 26,667 | — | ||||||
Repayment of Asset-Backed Notes | (7,411 | ) | (2,938 | ) | ||||
Distributions paid | (3,286 | ) | (3,181 | ) | ||||
Net cash provided by (used in) financing activities | 15,970 | (6,119 | ) | |||||
Net increase (decrease) in cash | 21,411 | (11,348 | ) | |||||
Cash: | ||||||||
Beginning of period | 8,417 | 25,341 | ||||||
End of period | $ | 29,828 | $ | 13,993 | ||||
Supplemental disclosure of cash flow information: | ||||||||
Cash paid for interest | $ | 1,032 | $ | 1,582 | ||||
Supplemental non-cash investing and financing activities: | ||||||||
Warrant investments received and recorded as unearned income | $ | 156 | $ | 106 | ||||
Distribution payable | $ | 3,783 | $ | 3,318 | ||||
End-of-term payments receivable | $ | 4,155 | $ | 3,730 | ||||
Net assets received in settlement of debt investment | $ | — | $ | 985 |
See Notes to Consolidated Financial Statements
6 |
Horizon Technology Finance Corporation and Subsidiaries
Consolidated Schedule of Investments (Unaudited)
March 31, 2015
(In thousands)
Principal | Cost of | Fair | ||||||||||||||
Portfolio Company (1) | Sector | Type of Investment (3)(4)(7)(10)(11) | Amount | Investments (6) | Value | |||||||||||
Debt Investments — 119.8% (9) | ||||||||||||||||
Debt Investments — Life Science — 28.7% (9) | ||||||||||||||||
Argos Therapeutics, Inc. (2)(5) | Biotechnology | Term Loan (9.25% cash (Libor + 8.75%; Floor 9.25%; | $ | 5,000 | $ | 4,878 | $ | 4,878 | ||||||||
Ceiling 10.75%), 5.00% ETP, Due 10/1/18) | ||||||||||||||||
New Haven Pharmaceuticals, Inc. (2) | Biotechnology | Term Loan (11.50% cash (Libor + 11.00%; Floor | 1,301 | 1,293 | 1,293 | |||||||||||
11.50%), 6.50% ETP, Due 11/1/17) | ||||||||||||||||
Term Loan (11.50% cash (Libor + 11.00%; Floor | 434 | 431 | 431 | |||||||||||||
11.50%), 6.50% ETP, Due 11/1/17) | ||||||||||||||||
Term Loan (10.50% cash (Libor + 10.00%; Floor | 2,000 | 1,969 | 1,969 | |||||||||||||
10.50%), 4.00% ETP, Due 7/1/18) | ||||||||||||||||
Palatin Technologies, Inc. (2)(5) | Biotechnology | Term Loan (9.00% cash (Libor + 8.50%; Floor | 5,000 | 4,924 | 4,924 | |||||||||||
9.00%), 5.00% ETP, Due 1/1/19) | ||||||||||||||||
Sample6, Inc. (2) | Biotechnology | Term Loan (9.50% cash (Libor + 9.00%; Floor | 1,555 | 1,549 | 1,549 | |||||||||||
9.50%; Ceiling 11.00%), 4.00% ETP, Due 4/1/18) | ||||||||||||||||
Term Loan (9.50% cash (Libor + 9.00%; Floor | 945 | 926 | 926 | |||||||||||||
9.50%; Ceiling 11.00%), 4.00% ETP, Due 4/1/18) | ||||||||||||||||
Term Loan (9.50% cash (Libor + 9.00%; Floor | 2,500 | 2,487 | 2,487 | |||||||||||||
9.50%; Ceiling 11.00%), 4.00% ETP, Due 4/1/18) | ||||||||||||||||
Sunesis Pharmaceuticals, Inc. (2)(5) | Biotechnology | Term Loan (8.95% cash, 4.65% ETP, Due 10/1/16) | 545 | 543 | 543 | |||||||||||
Term Loan (9.00% cash, 4.65% ETP, Due 10/1/16) | 818 | 810 | 810 | |||||||||||||
Xcovery Holding Company, LLC (2) | Biotechnology | Term Loan (12.50% cash, Due 8/1/15) | 211 | 210 | 210 | |||||||||||
Term Loan (12.50% cash, Due 8/1/15) | 266 | 266 | 266 | |||||||||||||
Term Loan (12.50% cash, Due 10/1/15) | 79 | 79 | 79 | |||||||||||||
Accuvein, Inc. (2) | Medical Device | Term Loan (10.40% cash (Libor + 9.90%; Floor | 4,000 | 3,959 | 3,959 | |||||||||||
10.40%; Ceiling 11.90%), 5.00% ETP, Due 2/1/18) | ||||||||||||||||
Term Loan (10.00% cash (Libor + 9.50%; Floor | 1,000 | 982 | 982 | |||||||||||||
10.00%; Ceiling 12.50%), 4.00% ETP, Due 7/1/18) | ||||||||||||||||
IntegenX Inc. (2) | Medical Device | Term Loan (10.75% cash (Libor + 10.25%; Floor | 3,750 | 3,689 | 3,689 | |||||||||||
10.75%; Ceiling 12.75%), 3.50% ETP, Due 7/1/18) | ||||||||||||||||
Lantos Technologies, Inc. (2) | Medical Device | Term Loan (10.50% cash (Libor + 10.00%; Floor | 3,500 | 3,453 | 3,453 | |||||||||||
10.50%; Ceiling 12.00%), 3.00% ETP, Due 2/1/18) | ||||||||||||||||
Mederi Therapeutics, Inc. (2) | Medical Device | Term Loan (10.75% cash (Libor + 10.25%; Floor | 3,000 | 2,972 | 2,972 | |||||||||||
10.75%; Ceiling 12.75%), 4.00% ETP, Due 7/1/17) | ||||||||||||||||
Term Loan (10.75% cash (Libor + 10.25%; Floor | 3,000 | 2,972 | 2,972 | |||||||||||||
10.75%; Ceiling 12.75%), 4.00% ETP, Due 7/1/17) | ||||||||||||||||
NinePoint Medical, Inc. (2) | Medical Device | Term Loan (9.25% cash (Libor + 8.75%; Floor | 5,000 | 4,918 | 4,918 | |||||||||||
9.25%), 4.50% ETP, Due 3/1/19) | ||||||||||||||||
Tryton Medical, Inc. (2) | Medical Device | Term Loan (10.41% cash (Prime + 7.16%), 2.50% ETP, | 2,625 | 2,605 | 2,605 | |||||||||||
Due 9/1/16) | ||||||||||||||||
ZetrOZ, Inc. (2) | Medical Device | Term Loan (11.00% cash (Libor + 10.50%; Floor | 1,500 | 1,429 | 1,429 | |||||||||||
11.00%; Ceiling 12.50%), 3.00% ETP, Due 4/1/18) | ||||||||||||||||
Total Debt Investments — Life Science | 47,344 | 47,344 | ||||||||||||||
Debt Investments — Technology — 69.1% (9) | ||||||||||||||||
Ekahau, Inc. (2) | Communications | Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17) | 1,142 | 1,132 | 1,132 | |||||||||||
Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17) | 381 | 377 | 377 | |||||||||||||
mBlox, Inc. (2) | Communications | Term Loan (11.50% cash (Libor + 11.00%; Floor | 5,000 | 4,970 | 4,970 | |||||||||||
11.50%; Ceiling 13.00%), 2.5% ETP, Due 7/1/18) | ||||||||||||||||
Term Loan (11.50% cash (Libor + 11.00%; Floor | 5,000 | 4,970 | 4,970 | |||||||||||||
11.50%; Ceiling 13.00%), 2.5% ETP, Due 7/1/18) | ||||||||||||||||
Overture Networks, Inc. (2) | Communications | Term Loan (10.75% cash, (Libor + 10.25%; Floor | 4,104 | 4,073 | 4,073 | |||||||||||
10.75%), 5.75% ETP, Due 12/1/17) | ||||||||||||||||
Term Loan (10.75% cash (Libor + 10.25%; Floor | 2,052 | 2,039 | 2,039 | |||||||||||||
10.75%), 5.75% ETP, Due 12/1/17) | ||||||||||||||||
Additech, Inc. (2) | Consumer-related Technologies | Term Loan (11.75% cash (Libor + 11.25%; Floor | 2,500 | 2,420 | 2,420 | |||||||||||
11.75%; Ceiling 13.25%), 4.00% ETP, Due 7/1/18) | ||||||||||||||||
Gwynnie Bee, Inc. (2) | Consumer-related Technologies | Term Loan (11.00% cash (Libor + 10.50%; Floor | 2,000 | 1,968 | 1,968 | |||||||||||
11.00%; Ceiling 12.50%), 2.0% ETP, Due 11/1/17) | ||||||||||||||||
Term Loan (11.00% cash (Libor + 10.50%; Floor | 1,000 | 976 | 976 | |||||||||||||
11.00%; Ceiling 12.50%), 2.0% ETP, Due 2/1/18) | ||||||||||||||||
Term Loan (11.00% cash (Libor + 10.50%; Floor | 1,000 | 982 | 982 | |||||||||||||
11.00%; Ceiling 12.50%), 2.0% ETP, Due 4/1/18) | ||||||||||||||||
Nanocomp Technologies, Inc. (2) | Networking | Term Loan (11.50% cash, 3.00% ETP, Due 11/1/17) | 948 | 932 | 932 | |||||||||||
Avalanche Technology, Inc. (2) | Semiconductors | Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%; | 1,983 | 1,975 | 1,975 | |||||||||||
Ceiling 11.75%), 2.40% ETP, Due 4/1/17) |
See Notes to Consolidated Financial Statements
7 |
Horizon Technology Finance Corporation and Subsidiaries
Consolidated Schedule of Investments (Unaudited)
March 31, 2015
(In thousands)
Principal | Cost of | Fair | ||||||||||||||
Portfolio Company (1) | Sector | Type of Investment (3)(4)(7)(10)(11) | Amount | Investments (6) | Value | |||||||||||
Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%; | 2,246 | 2,238 | 2,238 | |||||||||||||
Ceiling 11.75%) ,2.40% ETP, Due 10/1/18) | ||||||||||||||||
Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%; | 2,500 | 2,444 | 2,444 | |||||||||||||
Ceiling 11.75%), 2.00% ETP, Due 2/1/19) | ||||||||||||||||
eASIC Corporation (2) | Semiconductors | Term Loan (11.00% cash, 2.50% ETP, Due 10/1/17) | 2,000 | 1,984 | 1,984 | |||||||||||
Term Loan (10.75% cash, 2.50% ETP, Due 4/1/18) | 2,000 | 1,985 | 1,985 | |||||||||||||
InVisage Technologies, Inc. (2) | Semiconductors | Term Loan (12.00% cash (Libor + 11.50%; Floor | 2,550 | 2,483 | 2,483 | |||||||||||
12.00%; Ceiling 14.00%), 2.0% ETP, Due 4/1/18) | ||||||||||||||||
Term Loan (12.00% cash (Libor + 11.50%; Floor | 850 | 837 | 837 | |||||||||||||
12.00%; Ceiling 14.00%), 2.0% ETP, Due 10/1/18) | ||||||||||||||||
Luxtera, Inc. (2) | Semiconductors | Term Loan (10.25% cash (Libor + 9.75%; Floor 10.25%; | 2,475 | 2,442 | 2,442 | |||||||||||
Ceiling 12.25%), 13.00% ETP, Due 7/1/17) | ||||||||||||||||
Term Loan (10.25% cash (Libor + 9.75%; Floor 10.25%; | 1,381 | 1,376 | 1,376 | |||||||||||||
Ceiling 12.25%), 13.00% ETP, Due 7/1/17) | ||||||||||||||||
Term Loan (9.00% cash (Libor + 8.50%; Floor 9.00%), | 833 | 820 | 820 | |||||||||||||
4.50% ETP, Due 12/1/18) | ||||||||||||||||
NexPlanar Corporation (2) | Semiconductors | Term Loan (10.50% cash, 2.50% ETP, Due 12/1/16) | 2,086 | 2,073 | 2,073 | |||||||||||
Term Loan (10.50% cash, 2.50% ETP, Due 12/1/16) | 1,390 | 1,379 | 1,379 | |||||||||||||
Xtera Communications, Inc. (2) | Semiconductors | Term Loan (11.50% cash, 15.65% ETP, Due 12/31/16) | 5,655 | 5,544 | 5,544 | |||||||||||
Term Loan (11.50% cash, 21.75% ETP, Due 12/31/16) | 1,571 | 1,538 | 1,538 | |||||||||||||
Crowdstar, Inc. (2) | Software | Term Loan (10.75% cash (Libor + 10.25%; Floor | 2,000 | 1,958 | 1,958 | |||||||||||
10.75%), 3.00% ETP, Due 9/1/18) | ||||||||||||||||
Decisyon, Inc. (2) | Software | Term Loan (11.65% cash, 5.00% ETP, Due 9/1/16) | 2,538 | 2,523 | 2,523 | |||||||||||
Term Loan (11.65% cash, 5.00% ETP, Due 11/1/17) | 1,000 | 988 | 988 | |||||||||||||
Education Elements, Inc. (2) | Software | Term Loan (10.50% cash (Libor + 10.00%; Floor | 2,000 | 1,959 | 1,959 | |||||||||||
10.50%), 4.00% ETP, Due 1/1/19) | ||||||||||||||||
Lotame Solutions, Inc. (2) | Software | Term Loan (11.50% cash (Libor + 11.00%; Floor | 3,410 | 3,392 | 3,392 | |||||||||||
11.50%), 5.25% ETP, Due 9/1/17) | ||||||||||||||||
Term Loan (11.50% cash (Libor + 11.00%; Floor | 1,500 | 1,492 | 1,492 | |||||||||||||
11.50%), 5.25% ETP, Due 9/1/17) | ||||||||||||||||
Term Loan (11.50% cash (Libor + 11.00%; Floor | 2,100 | 2,072 | 2,072 | |||||||||||||
11.50%), 3.00% ETP, Due 4/1/18) | ||||||||||||||||
Netuitive, Inc. (2) | Software | Term Loan (12.75% cash, Due 7/1/16) | 1,590 | 1,582 | 1,582 | |||||||||||
Raydiance, Inc. (2) | Software | Term Loan (11.50% cash, 2.75% ETP, Due 9/1/16) | 3,008 | 2,992 | 2,992 | |||||||||||
Term Loan (11.50% cash, 2.75% ETP, Due 9/1/16) | 602 | 594 | 594 | |||||||||||||
Term Loan (11.50% cash (Libor + 11.00%; Floor | 3,000 | 2,959 | 2,959 | |||||||||||||
11.50%; Ceiling 13.50%), 2.75% ETP, Due 2/1/18) | ||||||||||||||||
Razorsight Corporation (2) | Software | Term Loan (11.75% cash, 3.00% ETP, Due 11/1/16) | 1,000 | 993 | 993 | |||||||||||
Term Loan (11.75% cash, 3.00% ETP, Due 8/1/16) | 854 | 847 | 847 | |||||||||||||
Term Loan (11.75% cash, 3.00% ETP, Due 7/1/17) | 913 | 903 | 903 | |||||||||||||
ScoreBig, Inc. (2) | Software | Term Loan (10.50% cash (Libor + 10.00%; Floor | 3,500 | 3,438 | 3,438 | |||||||||||
10.50%), 4.00% ETP, Due 4/1/19) | ||||||||||||||||
Term Loan (10.50% cash (Libor + 10.00%; Floor | 3,500 | 3,438 | 3,438 | |||||||||||||
10.50%), 4.00% ETP, Due 4/1/19) | ||||||||||||||||
SIGNiX, Inc. (2) | Software | Term Loan (11.50% cash (Libor + 11.00%; Floor | 3,000 | 2,907 | 2,907 | |||||||||||
11.50%), Due 7/1/18) | ||||||||||||||||
Social Intelligence Corp. (2) | Software | Term Loan (11.00% cash (Libor + 10.50%; Floor | 1,500 | 1,479 | 1,479 | |||||||||||
11.00%; Ceiling 13.00%), 3.50% ETP, Due 12/1/17) | ||||||||||||||||
SpringCM, Inc. (2) | Software | Term Loan (11.50% cash (Libor + 11.00%; Floor | 4,500 | 4,432 | 4,432 | |||||||||||
11.50%; Ceiling 13.00%), 2.00% ETP, Due 1/1/18) | ||||||||||||||||
Sys-Tech Solutions, Inc. (2) | Software | Term Loan (11.65% cash (Libor + 11.15%; Floor | 6,000 | 5,957 | 5,957 | |||||||||||
11.65%; Ceiling 12.65%), 4.50% ETP, Due 3/1/18) | ||||||||||||||||
Term Loan (11.65% cash (Libor + 11.15%; Floor | 5,000 | 4,956 | 4,956 | |||||||||||||
11.65%; Ceiling 12.65%), 9.00% ETP, Due 5/1/18) | ||||||||||||||||
VBrick Systems, Inc. (2) | Software | Term Loan (11.50% cash (Libor + 11.00%; Floor | 2,800 | 2,781 | 2,781 | |||||||||||
11.50%; Ceiling 13.50%), 5.00% ETP, Due 7/1/17) | ||||||||||||||||
Vidsys, Inc. (2) | Software | Term Loan (13.00% cash, 7.58% ETP, Due 7/1/15) | 3,000 | 2,998 | 2,998 | |||||||||||
Visage Mobile, Inc. (2) | Software | Term Loan (12.00% cash, 3.50% ETP, Due 9/1/16) | 556 | 552 | 552 | |||||||||||
xTech Holdings, Inc. (2) | Software | Term Loan (11.00% cash (Libor + 10.50%; Floor | 2,000 | 1,950 | 1,950 | |||||||||||
11.00%), 3.00% ETP, Due 4/1/19 | ||||||||||||||||
Total Debt Investments — Technology | 114,099 | 114,099 |
See Notes to Consolidated Financial Statements
8 |
Horizon Technology Finance Corporation and Subsidiaries
Consolidated Schedule of Investments (Unaudited)
March 31, 2015
(In thousands)
Principal | Cost of | Fair | ||||||||||||||
Portfolio Company (1) | Sector | Type of Investment (3)(4)(7)(10)(11) | Amount | Investments (6) | Value | |||||||||||
Debt Investments — Cleantech — 6.7% (9) | ||||||||||||||||
Renmatix, Inc. (2) | Alternative Energy | Term Loan (10.25% cash, 3.00% ETP, Due 2/1/16) | 913 | 911 | 911 | |||||||||||
Term Loan (10.25% cash, 3.00% ETP, Due 2/1/16) | 913 | 911 | 911 | |||||||||||||
Term Loan (10.25% cash, Due 10/1/16) | 3,049 | 3,035 | 3,035 | |||||||||||||
Semprius, Inc. (2)(8) | Alternative Energy | Term Loan (10.25% cash, 5.00% ETP, Due 6/1/16) | 2,069 | 2,049 | 2,049 | |||||||||||
Aurora Algae, Inc. (2) | Consumer-related Technologies | Term Loan (10.50% cash, 2.00% ETP, Due 5/1/15) | 161 | 161 | 161 | |||||||||||
Rypos, Inc. (2) | Energy Efficiency | Term Loan (11.80% cash, Due 1/1/17) | 2,550 | 2,529 | 2,529 | |||||||||||
Term Loan (11.80% cash, Due 9/1/17) | 1,000 | 988 | 988 | |||||||||||||
Tigo Energy, Inc. (2) | Energy Efficiency | Term Loan (13.00% cash, 3.16% ETP, Due 6/1/15) | 399 | 399 | 399 | |||||||||||
Total Debt Investments — Cleantech | 10,983 | 10,983 | ||||||||||||||
Debt Investments — Healthcare information and services — 15.3% (9) | ||||||||||||||||
Interleukin Genetics, Inc. (2)(5) | Diagnostics | Term Loan (9.00% cash (Libor + 8.50%; Floor 9.00%) | 5,000 | 4,848 | 4,848 | |||||||||||
4.50% ETP, Due 10/1/18) | ||||||||||||||||
LifePrint Group, Inc. (2) | Diagnostics | Term Loan (11.00% cash (Libor + 10.50%; Floor | 3,000 | 2,954 | 2,788 | |||||||||||
11.00%; Ceiling 12.50%), 3.00% ETP, Due 1/1/18) | ||||||||||||||||
Watermark Medical, Inc. (2) | Other Healthcare | Term Loan (10.00% cash (Libor + 9.50%; Floor 10.00%; | 3,500 | 3,492 | 3,492 | |||||||||||
Ceiling 11.00%); 4.00% ETP, Due 4/1/18) | ||||||||||||||||
Term Loan (10.00% cash (Libor + 9.50%; Floor 10.00%; | 3,500 | 3,492 | 3,492 | |||||||||||||
Ceiling 11.00%); 4.00% ETP, Due 4/1/18) | ||||||||||||||||
Term Loan (10.00% cash (Libor + 9.50%; Floor 10.00%; | 1,250 | 1,247 | 1,247 | |||||||||||||
Ceiling 11.00%); 4.00% ETP, Due 4/1/18) | ||||||||||||||||
Recondo Technology, Inc. (2) | Software | Term Loan (11.50% cash (Libor + 11.00%; Floor | 1,384 | 1,379 | 1,379 | |||||||||||
11.50%), 6.60% ETP, Due 12/1/17) | ||||||||||||||||
Term Loan (11.00% cash (Libor + 10.50%; Floor | 2,500 | 2,491 | 2,491 | |||||||||||||
11.00%), 4.50% ETP, Due 12/1/17) | ||||||||||||||||
Term Loan (10.50% cash (Libor + 10.00%; Floor | 2,500 | 2,491 | 2,491 | |||||||||||||
10.50%), 2.75% ETP, Due 12/1/17) | ||||||||||||||||
Term Loan (10.50% cash (Libor + 10.00%; Floor | 3,000 | 2,956 | 2,956 | |||||||||||||
10.50%), 2.50% ETP, Due 1/1/19) | ||||||||||||||||
Total Debt Investments — Healthcare information and services | 25,350 | 25,184 | ||||||||||||||
Total Debt Investments | 197,776 | 197,610 | ||||||||||||||
Warrant Investments — 3.1% (9) | ||||||||||||||||
Warrants — Life Science — 0.7% (9) | ||||||||||||||||
ACT Biotech Corporation | Biotechnology | 1,521,820 Preferred Stock Warrants | — | 83 | — | |||||||||||
Argos Therapeutics, Inc. (2)(5) | Biotechnology | 16,556 Common Stock Warrants | — | 33 | 20 | |||||||||||
Celsion Corporation (5) | Biotechnology | 5,708 Common Stock Warrants | — | 15 | — | |||||||||||
Inotek Pharmaceuticals Corporation (5) | Biotechnology | 33,762 Preferred Stock Warrants | — | 17 | 23 | |||||||||||
New Haven Pharmaceuticals, Inc. (2) | Biotechnology | 55,347 Preferred Stock Warrants | — | 42 | 134 | |||||||||||
Nivalis Theraputics, Inc., fka N30 Pharmaceuticals, Inc. | Biotechnology | 53,550 Common Stock Warrants | — | 122 | — | |||||||||||
Palatin Technologies, Inc. (2)(5) | Biotechnology | 333,333 Common Stock Warrants | — | 31 | 103 | |||||||||||
Revance Therapeutics, Inc. (5) | Biotechnology | 34,377 Common Stock Warrants | — | 68 | 226 | |||||||||||
Sample6, Inc. (2) | Biotechnology | 351,018 Preferred Stock Warrants | — | 45 | 38 | |||||||||||
Sunesis Pharmaceuticals, Inc. (5) | Biotechnology | 12,302 Common Stock Warrants | — | 6 | 6 | |||||||||||
Supernus Pharmaceuticals, Inc. (2)(5) | Biotechnology | 42,083 Preferred Stock Warrants | — | 93 | 322 | |||||||||||
Tranzyme, Inc. (2)(5) | Biotechnology | 6,460 Common Stock Warrants | — | 6 | — | |||||||||||
Accuvein, Inc. (2) | Medical Device | 75,769 Preferred Stock Warrants | — | 24 | 28 | |||||||||||
Direct Flow Medical, Inc. | Medical Device | 176,922 Preferred Stock Warrants | — | 144 | 39 | |||||||||||
EnteroMedics, Inc. (5) | Medical Device | 141,026 Common Stock Warrants | — | 347 | — | |||||||||||
IntegenX, Inc. (2) | Medical Device | 158,006 Preferred Stock Warrants | — | 33 | 31 | |||||||||||
Lantos Technologies, Inc. (2) | Medical Device | 858,545 Preferred Stock Warrants | — | 24 | 23 | |||||||||||
Mederi Therapeutics, Inc. (2) | Medical Device | 248,736 Preferred Stock Warrants | — | 26 | 39 | |||||||||||
Mitralign, Inc. (2) | Medical Device | 641,909 Preferred Stock Warrants | — | 52 | 36 | |||||||||||
NinePoint Medical, Inc. (2) | Medical Device | 410,959 Preferred Stock Warrants | — | 34 | 34 | |||||||||||
OraMetrix, Inc. (2) | Medical Device | 812,348 Preferred Stock Warrants | — | 78 | — | |||||||||||
Tryton Medical, Inc. (2) | Medical Device | 122,362 Preferred Stock Warrants | — | 15 | 13 | |||||||||||
ViOptix, Inc. | Medical Device | 375,763 Preferred Stock Warrants | — | 13 | — | |||||||||||
ZetrOZ, Inc. (2) | Medical Device | 475,561 Preferred Stock Warrants | — | 25 | 24 | |||||||||||
Total Warrants — Life Science | 1,376 | 1,139 | ||||||||||||||
Warrants — Technology — 1.9% (9) | ||||||||||||||||
Ekahau, Inc. (2) | Communications | 978,261 Preferred Stock Warrants | — | 33 | 19 | |||||||||||
OpenPeak, Inc. | Communications | 18,997 Common Stock Warrants | — | 89 | — | |||||||||||
Overture Networks, Inc. | Communications | 385,617 Preferred Stock Warrants | — | 55 | — |
See Notes to Consolidated Financial Statements
9 |
Horizon Technology Finance Corporation and Subsidiaries
Consolidated Schedule of Investments (Unaudited)
March 31, 2015
(In thousands)
Principal | Cost of | Fair | ||||||||||||||
Portfolio Company (1) | Sector | Type of Investment (3)(4)(7)(10)(11) | Amount | Investments (6) | Value | |||||||||||
Additech, Inc. (2) | Consumer-related Technologies | 150,000 Preferred Stock Warrants | — | 33 | 33 | |||||||||||
Everyday Health, Inc. (5) | Consumer-related Technologies | 43,783 Common Stock Warrants | — | 69 | 110 | |||||||||||
Gwynnie Bee, Inc. (2) | Consumer-related Technologies | 268,591 Preferred Stock Warrants | — | 68 | 436 | |||||||||||
SnagAJob.com, Inc. | Consumer-related Technologies | 365,396 Preferred Stock Warrants | — | 23 | 303 | |||||||||||
Tagged, Inc. | Consumer-related Technologies | 190,868 Preferred Stock Warrants | — | 26 | 63 | |||||||||||
XIOtech, Inc. | Data Storage | 2,217,979 Preferred Stock Warrants | — | 23 | 18 | |||||||||||
Cartera Commerce, Inc. | Internet and media | 90,909 Preferred Stock Warrants | — | 16 | 160 | |||||||||||
SimpleTuition, Inc. | Internet and media | 189,573 Preferred Stock Warrants | — | 63 | 27 | |||||||||||
IntelePeer, Inc. | Networking | 141,549 Preferred Stock Warrants | — | 39 | 4 | |||||||||||
Nanocomp Technologies, Inc. (2) | Networking | 272,728 Preferred Stock Warrants | — | 25 | 23 | |||||||||||
Aquion Energy, Inc. | Power Management | 115,051 Preferred Stock Warrants | — | 7 | 55 | |||||||||||
Avalanche Technology, Inc. (2) | Semiconductors | 352,828 Preferred Stock Warrants | — | 101 | 84 | |||||||||||
eASIC Corporation (2) | Semiconductors | 40,445 Preferred Stock Warrants | — | 25 | 26 | |||||||||||
InVisage Technologies, Inc. (2) | Semiconductors | 185,790 Preferred Stock Warrants | — | 47 | 45 | |||||||||||
Kaminario, Inc. | Semiconductors | 1,087,203 Preferred Stock Warrants | — | 59 | 62 | |||||||||||
Luxtera, Inc.(2) | Semiconductors | 2,304,667 Preferred Stock Warrants | — | 47 | 108 | |||||||||||
NexPlanar Corporation | Semiconductors | 216,001 Preferred Stock Warrants | — | 36 | 55 | |||||||||||
Soraa, Inc. (2) | Semiconductors | 180,000 Preferred Stock Warrants | — | 80 | 77 | |||||||||||
Xtera Communications, Inc. | Semiconductors | 983,607 Preferred Stock Warrants | — | 206 | — | |||||||||||
Bolt Solutions, Inc. (2) | Software | 202,892 Preferred Stock Warrants | — | 113 | 113 | |||||||||||
Clarabridge, Inc. | Software | 53,486 Preferred Stock Warrants | — | 14 | 104 | |||||||||||
Crowdstar, Inc. (2) | Software | 75,428 Preferred Stock Warrants | — | 14 | 14 | |||||||||||
Decisyon, Inc. (2) | Software | 457,876 Preferred Stock Warrants | — | 46 | 27 | |||||||||||
DriveCam, Inc. | Software | 71,639 Preferred Stock Warrants | — | 20 | 120 | |||||||||||
Education Elements, Inc. (2) | Software | 136,070 Preferred Stock Warrants | — | 16 | 16 | |||||||||||
Lotame Solutions, Inc. (2) | Software | 288,115 Preferred Stock Warrants | — | 23 | 258 | |||||||||||
Netuitive, Inc. | Software | 41,569 Preferred Stock Warrants | — | 48 | — | |||||||||||
Raydiance, Inc. (2) | Software | 1,051,120 Preferred Stock Warrants | — | 71 | 65 | |||||||||||
Razorsight Corporation (2) | Software | 259,404 Preferred Stock Warrants | — | 43 | 44 | |||||||||||
Riv Data Corp. (2) | Software | 237,361 Preferred Stock Warrants | — | 13 | 12 | |||||||||||
ScoreBig, Inc. (2) | Software | 481,198 Preferred Stock Warrants | — | 55 | 55 | |||||||||||
SIGNiX, Inc. (2) | Software | 63,365 Preferred Stock Warrants | — | 48 | 47 | |||||||||||
SpringCM, Inc. (2) | Software | 2,385,686 Preferred Stock Warrants | — | 55 | 52 | |||||||||||
Sys-Tech Solutions, Inc. | Software | 375,000 Preferred Stock Warrants | — | 242 | 510 | |||||||||||
Vidsys, Inc. | Software | 37,346 Preferred Stock Warrants | — | 23 | — | |||||||||||
Visage Mobile, Inc. | Software | 1,692,047 Preferred Stock Warrants | — | 19 | 12 | |||||||||||
xTech Holdings, Inc. (2) | Software | 111,111 Preferred Stock Warrants | — | 29 | 29 | |||||||||||
Total Warrants — Technology | 2,062 | 3,186 | ||||||||||||||
Warrants — Cleantech — 0.1% (9) | ||||||||||||||||
Renmatix, Inc. | Alternative Energy | 52,296 Preferred Stock Warrants | — | 68 | 65 | |||||||||||
Semprius, Inc. | Alternative Energy | 519,981 Preferred Stock Warrants | — | 25 | — | |||||||||||
Rypos, Inc. (2) | Energy Efficiency | 5,627 Preferred Stock Warrants | — | 44 | 36 | |||||||||||
Tigo Energy, Inc. (2) | Energy Efficiency | 804,604 Preferred Stock Warrants | — | 99 | 111 | |||||||||||
Total Warrants — Cleantech | 236 | 212 | ||||||||||||||
Warrants — Healthcare information and services — 0.4% (9) | ||||||||||||||||
Accumetrics, Inc. | Diagnostics | 100,928 Preferred Stock Warrants | — | 106 | 63 | |||||||||||
Candescent Health, Inc., fka Radisphere National Radiology Group, Inc (2) | Diagnostics | 519,992 Preferred Stock Warrants | — | 378 | — | |||||||||||
BioScale, Inc. (2) | Diagnostics | 315,618 Preferred Stock Warrants | — | 55 | — | |||||||||||
Helomics Corporation | Diagnostics | 13,461 Preferred Stock Warrants | — | 73 | — | |||||||||||
Interleukin Genetics, Inc. (2)(5) | Diagnostics | 2,492,523 Common Stock Warrants | — | 112 | 112 | |||||||||||
LifePrint Group, Inc. (2) | Diagnostics | 49,000 Preferred Stock Warrants | — | 29 | 27 | |||||||||||
Singulex, Inc. | Other Healthcare | 293,632 Preferred Stock Warrants | — | 44 | 141 | |||||||||||
Talyst, Inc. | Other Healthcare | 300,360 Preferred Stock Warrants | — | 100 | 35 | |||||||||||
Watermark Medical, Inc. (2) | Other Healthcare | 27,373 Preferred Stock Warrants | — | 74 | 61 | |||||||||||
Recondo Technology, Inc. (2) | Software | 556,796 Preferred Stock Warrants | — | 95 | 208 | |||||||||||
Total Warrants — Healthcare information and services | 1,066 | 647 | ||||||||||||||
Total Warrants | 4,740 | 5,184 | ||||||||||||||
Other Investments — 0.2% (9) | ||||||||||||||||
Vette Technology, LLC | Data Storage | Royalty Agreement Due 4/18/2019 | — | 4,512 | 300 | |||||||||||
Total Other Investments | 4,512 | 300 | ||||||||||||||
Equity — 0.7% (9) | ||||||||||||||||
Insmed Incorporated (5) | Biotechnology | 33,208 Common Stock | — | 239 | 691 |
See Notes to Consolidated Financial Statements
10 |
Horizon Technology Finance Corporation and Subsidiaries
Consolidated Schedule of Investments (Unaudited)
March 31, 2015
(In thousands)
Principal | Cost of | Fair | ||||||||||||||
Portfolio Company (1) | Sector | Type of Investment (3)(4)(7)(10)(11) | Amount | Investments (6) | Value | |||||||||||
Revance Therapeutics, Inc.(5) | Biotechnology | 4,861 Common Stock | — | 73 | 101 | |||||||||||
Sunesis Pharmaceuticals, Inc. (5) | Biotechnology | 78,493 Common Stock | — | 83 | 192 | |||||||||||
Overture Networks Inc. | Communications | 386,191 Common Stock | — | 482 | 222 | |||||||||||
Total Equity | 877 | 1,206 | ||||||||||||||
Total Portfolio Investment Assets — 123.8% (9) | $ | 207,905 | $ | 204,300 | ||||||||||||
Short Term Investments — Money Market Funds — 0.2% (9) | ||||||||||||||||
US Bank Money Market Deposit Account | $ | 399 | $ | 399 | ||||||||||||
Total Short Term Investments — Money Market Funds | $ | 399 | $ | 399 | ||||||||||||
Short Term Investments — Restricted Investments— 1.4% (9) | ||||||||||||||||
US Bank Money Market Deposit Account (2) | $ | 2,351 | $ | 2,351 | ||||||||||||
Total Short Term Investments — Restricted Investments | $ | 2,351 | $ | 2,351 |
(1) | All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States. | |
(2) | Has been pledged as collateral under the Key Facility or the 2013-1 Securitization. | |
(3) | All investments are less than 5% ownership of the class and ownership of the portfolio company. | |
(4) | All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not include end-of-term payments (“ETPs”) and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. All debt investments are at fixed rates for the term of the debt investment, unless otherwise indicated. For each debt investment, the current interest rate in effect as of March 31, 2015 is provided. | |
(5) | Portfolio company is a public company. | |
(6) | For debt investments, represents principal balance less unearned income. | |
(7) | Preferred and common stock warrants, equity interests and other investments are non-income producing. | |
(8) | Debt investment is on non-accrual status at March 31, 2015, and interest payments received were recognized as income on a cash basis. | |
(9) | Value as a percent of net assets. | |
(10) | The Company did not have any non-qualifying assets under Section 55(a) of the 1940 Act. Under the 1940 Act, the Company may not acquire any non-qualifying assets unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company’s total assets. | |
(11) |
ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee will be based on income that the Company has not yet received in cash.
|
See Notes to Consolidated Financial Statements
11 |
Horizon Technology Finance Corporation and Subsidiaries
Consolidated Schedule of Investments (Unaudited)
December 31, 2014
(In thousands)
Principal | Cost of | Fair | ||||||||||||||
Portfolio Company (1) | Sector | Type of Investment (3)(4)(7)(10)(11) | Amount | Investments (6) | Value | |||||||||||
Debt Investments — 144.1% (9) | ||||||||||||||||
Debt Investments — Life Science — 31.4% (9) | ||||||||||||||||
Argos Therapeutics, Inc. (2)(5) | Biotechnology | Term Loan (9.25% cash (Libor + 8.75%; Floor 9.25%; | $ | 5,000 | $ | 4,872 | $ | 4,872 | ||||||||
Ceiling 10.75%), 5.00% ETP, Due 10/1/18) | ||||||||||||||||
Inotek Pharmaceuticals Corporation (2) | Biotechnology | Term Loan (11.00% cash, 3.00% ETP, Due 10/1/16) | 2,795 | 2,777 | 2,777 | |||||||||||
New Haven Pharmaceuticals, Inc. (2) | Biotechnology | Term Loan (11.50% cash (Libor + 11.00%; Floor | 1,301 | 1,292 | 1,292 | |||||||||||
11.50%), 6.50% ETP, Due 11/1/17) | ||||||||||||||||
Term Loan (11.50% cash (Libor + 11.00%; Floor | 434 | 431 | 431 | |||||||||||||
11.50%), 6.50% ETP, Due 11/1/17) | ||||||||||||||||
Term Loan (10.50% cash (Libor + 10.00%; Floor | 2,000 | 1,967 | 1,967 | |||||||||||||
10.50%), 4.00% ETP, Due 7/1/18) | ||||||||||||||||
Palatin Technologies, Inc. (2)(5) | Biotechnology | Term Loan (9.00% cash (Libor + 8.50%; Floor | 5,000 | 4,919 | 4,919 | |||||||||||
9.00%), 5.00% ETP, Due 1/1/19) | ||||||||||||||||
Sample6, Inc. (2) | Biotechnology | Term Loan (9.50% cash (Libor + 9.00%; Floor | 1,555 | 1,548 | 1,548 | |||||||||||
9.50%; Ceiling 11.00%), 4.00% ETP, Due 4/1/18) | ||||||||||||||||
Term Loan (9.50% cash (Libor + 9.00%; Floor | 945 | 912 | 912 | |||||||||||||
9.50%; Ceiling 11.00%), 4.00% ETP, Due 4/1/18) | ||||||||||||||||
Sunesis Pharmaceuticals, Inc. (2)(5) | Biotechnology | Term Loan (8.95% cash, 3.75% ETP, Due 10/1/15) | 677 | 675 | 675 | |||||||||||
Term Loan (9.00% cash, 3.75% ETP, Due 10/1/15) | 1,016 | 1,008 | 1,008 | |||||||||||||
Xcovery Holding Company, LLC (2) | Biotechnology | Term Loan (12.50% cash, Due 8/1/15) | 292 | 292 | 292 | |||||||||||
Term Loan (12.50% cash, Due 8/1/15) | 459 | 459 | 459 | |||||||||||||
Term Loan (12.50% cash, Due 10/1/15) | 101 | 101 | 101 | |||||||||||||
Accuvein, Inc. (2) | Medical Device | Term Loan (10.40% cash (Libor + 9.90%; Floor | 4,000 | 3,956 | 3,956 | |||||||||||
10.40%; Ceiling 11.90%), 5.00% ETP, Due 2/1/18) | ||||||||||||||||
Term Loan (10.00% cash (Libor + 9.50%; Floor | 1,000 | 981 | 981 | |||||||||||||
10.00%; Ceiling 12.50%), 4.00% ETP, Due 7/1/18) | ||||||||||||||||
IntegenX Inc. (2) | Medical Device | Term Loan (10.75% cash (Libor + 10.25%; Floor | 3,750 | 3,685 | 3,685 | |||||||||||
10.75%; Ceiling 12.75%), 3.50% ETP, Due 7/1/18) | ||||||||||||||||
Lantos Technologies, Inc. (2) | Medical Device | Term Loan (10.50% cash (Libor + 10.00%; Floor | 3,500 | 3,449 | 3,449 | |||||||||||
10.50%; Ceiling 12.00%), 3.00% ETP, Due 2/1/18) | ||||||||||||||||
Mederi Therapeutics, Inc. (2) | Medical Device | Term Loan (10.75% cash (Libor + 10.25%; Floor | 3,000 | 2,969 | 2,969 | |||||||||||
10.75%; Ceiling 12.75%), 4.00% ETP, Due 7/1/17) | ||||||||||||||||
Term Loan (10.75% cash (Libor + 10.25%; Floor | 3,000 | 2,969 | 2,969 | |||||||||||||
10.75%; Ceiling 12.75%), 4.00% ETP, Due 7/1/17) | ||||||||||||||||
Tryton Medical, Inc. (2) | Medical Device | Term Loan (10.41% cash (Prime + 7.16%), 2.50% ETP, | 2,813 | 2,789 | 2,789 | |||||||||||
Due 9/1/16) | ||||||||||||||||
ZetrOZ, Inc. (2) | Medical Device | Term Loan (11.00% cash (Libor + 10.50%; Floor | 1,500 | 1,427 | 1,427 | |||||||||||
11.00%; Ceiling 12.50%), 3.00% ETP, Due 4/1/18) | ||||||||||||||||
Total Debt Investments — Life Science | 43,478 | 43,478 | ||||||||||||||
Debt Investments — Technology — 78.9% (9) | ||||||||||||||||
Ekahau, Inc. (2) | Communications | Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17) | 1,279 | 1,267 | 1,267 | |||||||||||
Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17) | 426 | 422 | 422 | |||||||||||||
mBlox, Inc. (2) | Communications | Term Loan (11.50% cash (Libor + 11.00%; Floor | 5,000 | 4,967 | 4,967 | |||||||||||
11.50%; Ceiling 13.00%), 2.5% ETP, Due 7/1/18) | ||||||||||||||||
Term Loan (11.50% cash (Libor + 11.00%; Floor | 5,000 | 4,967 | 4,967 | |||||||||||||
11.50%; Ceiling 13.00%), 2.5% ETP, Due 7/1/18) | ||||||||||||||||
Overture Networks, Inc. (2) | Communications | Term Loan (10.75% cash, (Libor + 10.25%; Floor | 4,104 | 4,071 | 4,071 | |||||||||||
10.75%), 5.75% ETP, Due 12/1/17) | ||||||||||||||||
Term Loan (10.75% cash (Libor + 10.25%; Floor | 2,052 | 2,038 | 2,038 | |||||||||||||
10.75%), 5.75% ETP, Due 12/1/17) | ||||||||||||||||
Additech, Inc. (2) | Consumer-related Technologies | Term Loan (11.75% cash (Libor + 11.25%; Floor | 2,500 | 2,417 | 2,417 | |||||||||||
11.75%; Ceiling 13.25%), 4.00% ETP, Due 7/1/18) | ||||||||||||||||
Gwynnie Bee, Inc. (2) | Consumer-related Technologies | Term Loan (11.00% cash (Libor + 10.50%; Floor | 2,000 | 1,966 | 1,966 | |||||||||||
11.00%; Ceiling 12.50%), 2.0% ETP, Due 11/1/17) | ||||||||||||||||
| Term Loan (11.00% cash (Libor + 10.50%; Floor | 1,000 | 974 | 974 | ||||||||||||
11.00%; Ceiling 12.50%), 2.0% ETP, Due 2/1/18) | ||||||||||||||||
Term Loan (11.00% cash (Libor + 10.50%; Floor | 1,000 | 980 | 980 | |||||||||||||
11.00%; Ceiling 12.50%), 2.0% ETP, Due 4/1/18) | ||||||||||||||||
Nanocomp Technologies, Inc. (2) | Networking | Term Loan (11.50% cash, 3.00% ETP, Due 11/1/17) | 1,000 | 981 | 981 |
12 |
Avalanche Technology, Inc. (2) | Semiconductors | Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%; | 1,983 | 1,972 | 1,972 | |||||||||||
Ceiling 11.75%), 2.40% ETP, Due 4/1/17) | ||||||||||||||||
Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%; | 2,246 | 2,179 | 2,179 |
See Notes to Consolidated Financial Statements
13 |
Horizon Technology Finance Corporation and Subsidiaries
Consolidated Schedule of Investments (Unaudited)
December 31, 2014
(In thousands)
Principal | Cost of | Fair | ||||||||||||||
Portfolio Company (1) | Sector | Type of Investment (3)(4)(7)(10)(11) | Amount | Investments (6) | Value | |||||||||||
Ceiling 11.75%) ,2.40% ETP, Due 10/1/18) | ||||||||||||||||
eASIC Corporation (2) | Semiconductors | Term Loan (11.00% cash, 2.50% ETP, Due 4/1/17) | 2,000 | 1,982 | 1,982 | |||||||||||
Term Loan (10.75% cash, 2.50% ETP, Due 4/1/18) | 2,000 | 1,983 | 1,983 | |||||||||||||
InVisage Technologies, Inc. (2) | Semiconductors | Term Loan (12.00% cash (Libor + 11.50%; Floor | 2,550 | 2,469 | 2,469 | |||||||||||
12.00%; Ceiling 14.00%), 2.0% ETP, Due 4/1/18) | ||||||||||||||||
Kaminario, Inc. (2) | Semiconductors | Term Loan (10.50% cash, 2.50% ETP, Due 11/1/16) | 2,275 | 2,255 | 2,255 | |||||||||||
Term Loan (10.50% cash, 2.50% ETP, Due 11/1/16) | 2,275 | 2,255 | 2,255 | |||||||||||||
Luxtera, Inc. (2) | Semiconductors | Term Loan (10.25% cash, 13.00% ETP, Due 7/1/17) | 2,632 | 2,590 | 2,590 | |||||||||||
Term Loan (10.25% cash, 13.00% ETP, Due 7/1/17) | 1,469 | 1,462 | 1,462 | |||||||||||||
NexPlanar Corporation (2) | Semiconductors | Term Loan (10.50% cash, 2.50% ETP, Due 12/1/16) | 2,368 | 2,352 | 2,352 | |||||||||||
Term Loan (10.50% cash, 2.50% ETP, Due 12/1/16) | 1,579 | 1,564 | 1,564 | |||||||||||||
Xtera Communications, Inc. (2) | Semiconductors | Term Loan (11.50% cash, 15.65% ETP, Due 1/1/17) | 5,846 | 5,708 | 5,708 | |||||||||||
Term Loan (11.50% cash, 21.75% ETP, Due 1/1/17) | 1,624 | 1,584 | 1,584 | |||||||||||||
Courion Corporation (2) | Software | Term Loan (11.45% cash, Due 10/1/15) | 1,279 | 1,277 | 1,277 | |||||||||||
Term Loan (11.45% cash, Due 10/1/15) | 1,279 | 1,277 | 1,277 | |||||||||||||
Crowdstar, Inc. (2) | Software | Term Loan (10.75% cash (Libor + 10.25%; Floor | 2,000 | 1,956 | 1,956 | |||||||||||
10.75%), 3.00% ETP, Due 9/1/18) | ||||||||||||||||
Decisyon, Inc. (2) | Software | Term Loan (11.65% cash, 5.00% ETP, Due 9/1/16) | 2,919 | 2,899 | 2,899 | |||||||||||
Term Loan (11.65% cash, 5.00% ETP, Due 11/1/17) | 1,000 | 986 | 986 | |||||||||||||
Lotame Solutions, Inc. (2) | Software | Term Loan (11.50% cash (Libor + 11.00%; Floor | 3,410 | 3,390 | 3,390 | |||||||||||
11.50%), 5.25% ETP, Due 9/1/17) | ||||||||||||||||
Term Loan (11.50% cash (Libor + 11.00%; Floor | 1,500 | 1,491 | 1,491 | |||||||||||||
11.50%), 5.25% ETP, Due 9/1/17) | ||||||||||||||||
Term Loan (11.50% cash (Libor + 11.00%; Floor | 2,100 | 2,070 | 2,070 | |||||||||||||
11.50%), 3.00% ETP, Due 4/1/18) | ||||||||||||||||
Netuitive, Inc. (2) | Software | Term Loan (12.75% cash, Due 7/1/16) | 1,717 | 1,707 | 1,707 | |||||||||||
Raydiance, Inc. (2) | Software | Term Loan (11.50% cash, 2.75% ETP, Due 9/1/16) | 3,490 | 3,468 | 3,468 | |||||||||||
Term Loan (11.50% cash, 2.75% ETP, Due 9/1/16) | 698 | 688 | 688 | |||||||||||||
Term Loan (11.50% cash (Libor + 11.00%; Floor | 3,000 | 2,955 | 2,955 | |||||||||||||
11.50%; Ceiling 13.50%), 2.75% ETP, Due 2/1/18) | ||||||||||||||||
Razorsight Corporation (2) | Software | Term Loan (11.75% cash, 3.00% ETP, Due 11/1/16) | 1,142 | 1,132 | 1,132 | |||||||||||
Term Loan (11.75% cash, 3.00% ETP, Due 8/1/16) | 1,000 | 990 | 990 | |||||||||||||
Term Loan (11.75% cash, 3.00% ETP, Due 7/1/17) | 1,000 | 988 | 988 | |||||||||||||
SIGNiX, Inc. (2) | Software | Term Loan (11.50% cash (Libor + 11.00%; Floor | 3,000 | 2,902 | 2,902 | |||||||||||
11.50%), Due 7/1/18) | ||||||||||||||||
Social Intelligence Corp. (2) | Software | Term Loan (11.00% cash (Libor + 10.50%; Floor | 1,500 | 1,477 | 1,477 | |||||||||||
11.00%; Ceiling 13.00%), 3.50% ETP, Due 12/1/17) | ||||||||||||||||
SpringCM, Inc. (2) | Software | Term Loan (11.50% cash (Libor + 11.00%; Floor | 4,500 | 4,412 | 4,412 | |||||||||||
11.50%; Ceiling 13.00%), 2.00% ETP, Due 1/1/18) | ||||||||||||||||
Sys-Tech Solutions, Inc. (2) | Software | Term Loan (11.65% cash (Libor + 11.15%; Floor | 6,000 | 5,954 | 5,954 | |||||||||||
11.65%; Ceiling 12.65%), 4.50% ETP, Due 3/1/18) | ||||||||||||||||
Term Loan (11.65% cash (Libor + 11.15%; Floor | 5,000 | 4,952 | 4,952 | |||||||||||||
11.65%; Ceiling 12.65%), 9.00% ETP, Due 5/1/18) | ||||||||||||||||
VBrick Systems, Inc. (2) | Software | Term Loan (11.50% cash (Libor + 11.00%; Floor | 3,000 | 2,979 | 2,979 | |||||||||||
11.50%; Ceiling 13.50%), 5.00% ETP, Due 7/1/17) | ||||||||||||||||
Vidsys, Inc. (2) | Software | Term Loan (11.00% cash, 7.58% ETP, Due 4/1/15) | 3,000 | 2,993 | 2,993 | |||||||||||
Visage Mobile, Inc. (2) | Software | Term Loan (12.00% cash, 3.50% ETP, Due 9/1/16) | 645 | 640 | 640 | |||||||||||
Total Debt Investments — Technology | 108,988 | 108,988 | ||||||||||||||
Debt Investments — Cleantech — 9.3% (9) | ||||||||||||||||
Renmatix, Inc. (2) | Alternative Energy | Term Loan (10.25% cash, 3.00% ETP, Due 2/1/16) | 1,148 | 1,145 | 1,145 | |||||||||||
Term Loan (10.25% cash, 3.00% ETP, Due 2/1/16) | 1,148 | 1,145 | 1,145 | |||||||||||||
Term Loan (10.25% cash, Due 10/1/16) | 3,488 | 3,469 | 3,469 | |||||||||||||
Semprius, Inc. (2)(8) | Alternative Energy | Term Loan (10.25% cash, 2.50% ETP, Due 6/1/16) | 2,432 | 2,432 | 2,250 | |||||||||||
Aurora Algae, Inc. (2) | Consumer-related Technologies | Term Loan (10.50% cash, 2.00% ETP, Due 5/1/15) | 397 | 396 | 396 | |||||||||||
Rypos, Inc. (2) | Energy Efficiency | Term Loan (11.80% cash, Due 1/1/17) | 2,670 | 2,643 | 2,643 | |||||||||||
Term Loan (11.80% cash, Due 9/1/17) | 1,000 | 986 | 986 | |||||||||||||
Tigo Energy, Inc. (2) | Energy Efficiency | Term Loan (13.00% cash, 3.16% ETP, Due 6/1/15) | 786 | 785 | 785 | |||||||||||
Total Debt Investments — Cleantech | 13,001 | 12,819 | ||||||||||||||
Debt Investments — Healthcare information and services — 24.5% (9) | ||||||||||||||||
Interleukin Genetics, Inc. (2)(5) | Diagnostics | Term Loan (9.00% cash (Libor + 8.50%; Floor 9.00%) | 5,000 | 4,837 | 4,837 | |||||||||||
4.50% ETP, Due 10/1/18) | ||||||||||||||||
LifePrint Group, Inc. (2) | Diagnostics | Term Loan (11.00% cash (Libor + 10.50%; Floor | 3,000 | 2,949 | 2,747 |
See Notes to Consolidated Financial Statements
14 |
Horizon Technology Finance Corporation and Subsidiaries
Consolidated Schedule of Investments (Unaudited)
December 31, 2014
(In thousands)
Principal | Cost of | Fair | ||||||||||||||
Portfolio Company (1) | Sector | Type of Investment (3)(4)(7)(10)(11) | Amount | Investments (6) | Value | |||||||||||
11.00%; Ceiling 12.50%), 3.00% ETP, Due 1/1/18) | ||||||||||||||||
Radisphere National Radiology Group, Inc. (2) | Diagnostics | Revolver (11.25% cash (Prime + 8.00%), Due 10/1/15) | 10,092 | 10,053 | 10,053 | |||||||||||
Watermark Medical, Inc. (2) | Other Healthcare | Term Loan (12.00% cash, 4.00% ETP, Due 4/1/17) | 3,500 | 3,473 | 3,473 | |||||||||||
Term Loan (12.00% cash, 4.00% ETP, Due 4/1/17) | 3,500 | 3,473 | 3,473 | |||||||||||||
Recondo Technology, Inc. (2) | Software | Term Loan (11.50% cash (Libor + 11.00%; Floor | 1,384 | 1,379 | 1,379 | |||||||||||
11.50%), 6.60% ETP, Due 12/1/17) | ||||||||||||||||
Term Loan (11.00% cash (Libor + 10.50%; Floor | 2,500 | 2,490 | 2,490 | |||||||||||||
11.00%), 4.50% ETP, Due 12/1/17) | ||||||||||||||||
Term Loan (10.50% cash (Libor + 10.00%; Floor | 2,500 | 2,490 | 2,490 | |||||||||||||
10.50%), 2.75% ETP, Due 12/1/17) | ||||||||||||||||
Term Loan (10.50% cash (Libor + 10.00%; Floor | 3,000 | 2,953 | 2,953 | |||||||||||||
10.50%), 2.50% ETP, Due 1/1/19) | ||||||||||||||||
Total Debt Investments — Healthcare information and services | 34,097 | 33,895 | ||||||||||||||
Total Debt Investments | 199,564 | 199,180 | ||||||||||||||
Warrant Investments — 3.4% (9) | ||||||||||||||||
Warrants — Life Science — 0.6% (9) | ||||||||||||||||
ACT Biotech Corporation | Biotechnology | 1,521,820 Preferred Stock Warrants | — | 83 | — | |||||||||||
Argos Therapeutics, Inc. (2)(5) | Biotechnology | 16,556 Common Stock Warrants | — | 33 | 31 | |||||||||||
Celsion Corporation (5) | Biotechnology | 5,708 Common Stock Warrants | — | 15 | — | |||||||||||
Inotek Pharmaceuticals Corporation | Biotechnology | 33,762 Preferred Stock Warrants | — | 17 | 15 | |||||||||||
N30 Pharmaceuticals, Inc. | Biotechnology | 53,550 Common Stock Warrants | — | 122 | — | |||||||||||
New Haven Pharmaceuticals, Inc. (2) | Biotechnology | 55,347 Preferred Stock Warrants | — | 42 | 136 | |||||||||||
Palatin Technologies, Inc. (2)(5) | Biotechnology | 333,333 Common Stock Warrants | — | 31 | 31 | |||||||||||
Revance Therapeutics, Inc. (5) | Biotechnology | 34,377 Common Stock Warrants | — | 68 | 120 | |||||||||||
Sample6, Inc. (2) | Biotechnology | 351,018 Preferred Stock Warrants | — | 45 | 39 | |||||||||||
Supernus Pharmaceuticals, Inc. (2)(5) | Biotechnology | 42,083 Preferred Stock Warrants | — | 93 | 165 | |||||||||||
Tranzyme, Inc. (2)(5) | Biotechnology | 6,460 Common Stock Warrants | — | 6 | — | |||||||||||
Accuvein, Inc. (2) | Medical Device | 75,769 Preferred Stock Warrants | — | 24 | 29 | |||||||||||
Direct Flow Medical, Inc. | Medical Device | 176,922 Preferred Stock Warrants | — | 144 | 40 | |||||||||||
EnteroMedics, Inc. (5) | Medical Device | 141,026 Common Stock Warrants | — | 347 | — | |||||||||||
IntegenX, Inc. (2) | Medical Device | 158,006 Preferred Stock Warrants | — | 33 | 31 | |||||||||||
Lantos Technologies, Inc. (2) | Medical Device | 858,545 Preferred Stock Warrants | — | 24 | 23 | |||||||||||
Mederi Therapeutics, Inc. (2) | Medical Device | 248,736 Preferred Stock Warrants | — | 26 | 40 | |||||||||||
Mitralign, Inc. (2) | Medical Device | 641,909 Preferred Stock Warrants | — | 52 | 37 | |||||||||||
OraMetrix, Inc. (2) | Medical Device | 812,348 Preferred Stock Warrants | — | 78 | — | |||||||||||
Tengion, Inc. (2)(5) | Medical Device | 1,864,876 Common Stock Warrants | — | 123 | — | |||||||||||
Tryton Medical, Inc. (2) | Medical Device | 122,362 Preferred Stock Warrants | — | 15 | 13 | |||||||||||
ViOptix, Inc. | Medical Device | 375,763 Preferred Stock Warrants | — | 13 | — | |||||||||||
ZetrOZ, Inc. (2) | Medical Device | 475,561 Preferred Stock Warrants | — | 25 | 24 | |||||||||||
Total Warrants — Life Science | 1,459 | 774 | ||||||||||||||
Warrants — Technology — 2.2% (9) | ||||||||||||||||
Ekahau, Inc. (2) | Communications | 978,261 Preferred Stock Warrants | — | 33 | 19 | |||||||||||
OpenPeak, Inc. | Communications | 18,997 Common Stock Warrants | — | 89 | — | |||||||||||
Overture Networks, Inc. | Communications | 385,617 Preferred Stock Warrants | — | 56 | — | |||||||||||
Additech, Inc. (2) | Consumer-related Technologies | 150,000 Preferred Stock Warrants | — | 33 | 33 | |||||||||||
Everyday Health, Inc. (5) | Consumer-related Technologies | 43,783 Common Stock Warrants | — | 69 | 179 | |||||||||||
Gwynnie Bee, Inc. (2) | Consumer-related Technologies | 268,591 Preferred Stock Warrants | — | 68 | 312 | |||||||||||
SnagAJob.com, Inc. | Consumer-related Technologies | 365,396 Preferred Stock Warrants | — | 23 | 305 | |||||||||||
Tagged, Inc. | Consumer-related Technologies | 190,868 Preferred Stock Warrants | — | 26 | 62 | |||||||||||
XIOtech, Inc. | Data Storage | 2,217,979 Preferred Stock Warrants | — | 22 | 18 | |||||||||||
Cartera Commerce, Inc. | Internet and media | 90,909 Preferred Stock Warrants | — | 16 | 159 | |||||||||||
SimpleTuition, Inc. | Internet and media | 189,573 Preferred Stock Warrants | — | 63 | 29 | |||||||||||
IntelePeer, Inc. | Networking | 141,549 Preferred Stock Warrants | — | 39 | 33 | |||||||||||
Nanocomp Technologies, Inc. (2) | Networking | 272,728 Preferred Stock Warrants | — | 25 | 24 | |||||||||||
Aquion Energy, Inc. | Power Management | 115,051 Preferred Stock Warrants | — | 7 | 56 | |||||||||||
Avalanche Technology, Inc. (2) | Semiconductors | 352,828 Preferred Stock Warrants | — | 101 | 98 | |||||||||||
eASIC Corporation (2) | Semiconductors | 40,445 Preferred Stock Warrants | — | 25 | 28 | |||||||||||
InVisage Technologies, Inc. (2) | Semiconductors | 165,147 Preferred Stock Warrants | — | 43 | 41 | |||||||||||
Kaminario, Inc. | Semiconductors | 1,087,203 Preferred Stock Warrants | — | 59 | 64 | |||||||||||
Luxtera, Inc. | Semiconductors | 2,087,766 Preferred Stock Warrants | — | 43 | 105 |
See Notes to Consolidated Financial Statements
15 |
Horizon Technology Finance Corporation and Subsidiaries
Consolidated Schedule of Investments (Unaudited)
December 31, 2014
(In thousands)
Principal | Cost of | Fair | ||||||||||||||
Portfolio Company (1) | Sector | Type of Investment (3)(4)(7)(10)(11) | Amount | Investments (6) | Value | |||||||||||
NexPlanar Corporation | Semiconductors | 216,001 Preferred Stock Warrants | — | 36 | 56 | |||||||||||
Soraa, Inc. (2) | Semiconductors | 180,000 Preferred Stock Warrants | — | 80 | 77 | |||||||||||
Xtera Communications, Inc. | Semiconductors | 983,607 Preferred Stock Warrants | — | 206 | — | |||||||||||
Bolt Solutions, Inc. (2) | Software | 202,892 Preferred Stock Warrants | — | 113 | 118 | |||||||||||
Clarabridge, Inc. | Software | 53,486 Preferred Stock Warrants | — | 14 | 104 | |||||||||||
Courion Corporation | Software | 772,543 Preferred Stock Warrants | — | 107 | — | |||||||||||
Crowdstar, Inc. (2) | Software | 75,428 Preferred Stock Warrants | — | 14 | 14 | |||||||||||
Decisyon, Inc. (2) | Software | 457,876 Preferred Stock Warrants | — | 46 | 28 | |||||||||||
DriveCam, Inc. | Software | 71,639 Preferred Stock Warrants | — | 20 | 121 | |||||||||||
Lotame Solutions, Inc. (2) | Software | 288,115 Preferred Stock Warrants | — | 23 | 160 | |||||||||||
Netuitive, Inc. | Software | 41,569 Preferred Stock Warrants | — | 48 | — | |||||||||||
Raydiance, Inc. (2) | Software | 1,051,120 Preferred Stock Warrants | — | 71 | 67 | |||||||||||
Razorsight Corporation (2) | Software | 259,404 Preferred Stock Warrants | — | 43 | 44 | |||||||||||
SIGNiX, Inc. (2) | Software | 63,365 Preferred Stock Warrants | — | 48 | 48 | |||||||||||
Riv Data Corp. (2) | Software | 237,361 Preferred Stock Warrants | — | 13 | 12 | |||||||||||
SpringCM, Inc. (2) | Software | 2,385,686 Preferred Stock Warrants | — | 55 | 53 | |||||||||||
Sys-Tech Solutions, Inc. | Software | 375,000 Preferred Stock Warrants | — | 242 | 536 | |||||||||||
Vidsys, Inc. | Software | 37,346 Preferred Stock Warrants | — | 23 | — | |||||||||||
Visage Mobile, Inc. | Software | 1,692,047 Preferred Stock Warrants | — | 19 | 17 | |||||||||||
Total Warrants — Technology | 2,061 | 3,020 | ||||||||||||||
Warrants — Cleantech — 0.1% (9) | ||||||||||||||||
Renmatix, Inc. | Alternative Energy | 52,296 Preferred Stock Warrants | — | 67 | 67 | |||||||||||
Semprius, Inc. | Alternative Energy | 519,981 Preferred Stock Warrants | — | 25 | — | |||||||||||
Rypos, Inc. (2) | Energy Efficiency | 5,627 Preferred Stock Warrants | — | 44 | 40 | |||||||||||
Tigo Energy, Inc. (2) | Energy Efficiency | 804,604 Preferred Stock Warrants | — | 99 | 33 | |||||||||||
Total Warrants — Cleantech | 235 | 140 | ||||||||||||||
Warrants — Healthcare information and services — 0.5% (9) | ||||||||||||||||
Accumetrics, Inc. | Diagnostics | 100,928 Preferred Stock Warrants | — | 107 | 63 | |||||||||||
BioScale, Inc. (2) | Diagnostics | 315,618 Preferred Stock Warrants | — | 55 | — | |||||||||||
LifePrint Group, Inc. (2) | Diagnostics | 49,000 Preferred Stock Warrants | — | 29 | 29 | |||||||||||
Interleukin Genetics, Inc. (2)(5) | Diagnostics | 2,492,523 Common Stock Warrants | — | 112 | 112 | |||||||||||
Helomics Corporation, fka Precision Therapeutics, Inc. | Diagnostics | 13,461 Preferred Stock Warrants | — | 73 | — | |||||||||||
Radisphere National Radiology Group, Inc. (2) | Diagnostics | 519,992 Preferred Stock Warrants | — | 378 | — | |||||||||||
Singulex, Inc. | Other Healthcare | 293,632 Preferred Stock Warrants | — | 44 | 141 | |||||||||||
Talyst, Inc. | Other Healthcare | 300,360 Preferred Stock Warrants | — | 100 | 52 | |||||||||||
Watermark Medical, Inc. | Other Healthcare | 12,216 Preferred Stock Warrants | — | 67 | 62 | |||||||||||
Recondo Technology, Inc. (2) | Software | 556,796 Preferred Stock Warrants | — | 95 | 210 | |||||||||||
Total Warrants — Healthcare information and services | 1,060 | 669 | ||||||||||||||
Total Warrants | 4,815 | 4,603 | ||||||||||||||
Other Investments — 0.2% (9) | ||||||||||||||||
Vette Technology, LLC | Data Storage | Royalty Agreement Due 4/18/2019 | — | 4,582 | 300 | |||||||||||
Total Other Investments | 4,582 | 300 | ||||||||||||||
Equity — 0.7% (9) | ||||||||||||||||
Insmed Incorporated (5) | Biotechnology | 33,208 Common Stock | — | 239 | 514 | |||||||||||
Revance Therapeutics, Inc.(5) | Biotechnology | 4,861 Common Stock | — | 73 | 82 | |||||||||||
Sunesis Pharmaceuticals, Inc. (5) | Biotechnology | 78,493 Common Stock | — | 83 | 200 | |||||||||||
Overture Networks Inc. | Communications | 386,191 Common Stock | — | 482 | 222 | |||||||||||
Total Equity | 877 | 1,018 | ||||||||||||||
Total Portfolio Investment Assets — 148.4% (9) | $ | 209,838 | $ | 205,101 | ||||||||||||
Short Term Investments — Money Market Funds — 0.0% (9) | ||||||||||||||||
US Bank Money Market Deposit Account | $ | 27 | $ | 27 | ||||||||||||
Total Short Term Investments — Money Market Funds | $ | 27 | $ | 27 | ||||||||||||
Short Term Investments — Restricted Investments— 2.1% (9) | ||||||||||||||||
US Bank Money Market Deposit Account (2) | $ | 2,906 | $ | 2,906 | ||||||||||||
Total Short Term Investments — Restricted Investments | $ | 2,906 | $ | 2,906 |
See Notes to Consolidated Financial Statements
16 |
Horizon Technology Finance Corporation and Subsidiaries
Consolidated Schedule of Investments (Unaudited)
December 31, 2014
(In thousands)
(1) | All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States. | |
(2) | Has been pledged as collateral under the Key Facility or 2013-1 Securitization. | |
(3) | All investments are less than 5% ownership of the class and ownership of the portfolio company. | |
(4) | All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not include ETP and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. All debt investments are at fixed rates for the term of the debt investment, unless otherwise indicated. For each debt investment, the current interest rate in effect as of December 31, 2014 is provided. | |
(5) | Portfolio company is a public company. | |
(6) | For debt investments, represents principal balance less unearned income. | |
(7) | Preferred and common stock warrants, equity interests and other investments are non-income producing. | |
(8) | Debt investment is on non-accrual status at December 31, 2014, and interest payments received were recognized as income on a cash basis. | |
(9) | Value as a percent of net assets. | |
(10) | The Company did not have any non-qualifying assets under Section 55(a) of the 1940 Act. Under the 1940 Act, the Company may not acquire any non-qualifying assets unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company’s total assets. | |
(11) | ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee will be based on income that the Company has not yet received in cash. |
See Notes to Consolidated Financial Statements
17 |
Horizon Technology Finance Corporation and Subsidiaries
Notes to Consolidated Financial Statements
Note 1. Organization
Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 and is an externally managed, non-diversified, closed-end investment company. The Company has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). In addition, for tax purposes, the Company has elected to be treated as a regulated investment company (“RIC”) as defined under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company generally is not subject to corporate-level federal income tax on the portion of its taxable income and capital gains the Company distributes to its stockholders. The Company primarily makes secured debt investments to development-stage companies in the technology, life science, healthcare information and services and cleantech industries. All of the Company’s debt investments consist of loans secured by all of, or a portion of, the applicable debtor company’s tangible and intangible assets.
On October 28, 2010, the Company completed an initial public offering (“IPO”) and its common stock trades on the NASDAQ Global Select Market under the symbol “HRZN”. The Company was formed to continue and expand the business of Compass Horizon Funding Company LLC (“CHF”), a Delaware limited liability company, which commenced operations in March 2008 and became the Company’s wholly owned subsidiary upon the completion of the Company’s IPO.
Horizon Credit I LLC (“Credit I”) was formed as a Delaware limited liability company on January 23, 2008, with CHF as its sole equity member. Credit I is a separate legal entity from the Company and CHF. There has been no activity at Credit I during the three months ended March 31, 2015.
Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, with the Company as its sole equity member. Credit II is a special purpose bankruptcy remote entity and is a separate legal entity from the Company. Any assets conveyed to Credit II are not available to creditors of the Company or any other entity other than Credit II’s lenders.
Horizon Credit III LLC (“Credit III”) was formed as a Delaware limited liability company on May 30, 2012, with the Company as the sole equity member. Credit III is a separate legal entity from the Company. There has been no activity at Credit III during the three months ended March 31, 2015.
Longview SBIC GP LLC and Longview SBIC LP (collectively, “Horizon SBIC”) were formed as a Delaware limited liability company and Delaware limited partnership, respectively, on February 11, 2011. Horizon SBIC are wholly owned subsidiaries of the Company and were formed in anticipation of obtaining a license to operate a small business investment company from the U. S. Small Business Administration. There has been no activity in Horizon SBIC since its inception.
The Company formed Horizon Funding 2013-1 LLC (“2013-1 LLC”) as a Delaware limited liability company on June 7, 2013 and Horizon Funding Trust 2013-1 (“2013-1 Trust” and, together with 2013-1 LLC, the “2013-1 Entities”) as a Delaware trust on June 18, 2013. The 2013-1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2013-1 Entities for purposes of securitizing $189.3 million of secured loans (the “2013-1 Securitization”) and issuing fixed-rate asset-backed notes in an aggregate principal amount of $90 million (the “Asset-Backed Notes”).
The Company has also established additional wholly owned subsidiaries, each of which is structured as a Delaware limited liability company, to hold the assets of portfolio companies acquired in connection with foreclosure or bankruptcy. Each is a separate legal entity from the Company.
The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments the Company makes and capital appreciation from the warrants the Company receives when making such debt investments. The Company has entered into an amended and restated investment management agreement (the “Investment Management Agreement”) with Horizon Technology Finance Management LLC (the “Advisor”), under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company.
18 |
Horizon Technology Finance Corporation and Subsidiaries
Notes to Consolidated Financial Statements
On March 24, 2015, the Company completed a follow-on public offering of 2,000,000 shares of its common stock at a public offering price of $13.95 per share, for total net proceeds to the Company of $26.7 million, after deducting underwriting commission and discounts and other offering expenses.
Note 2. Basis of presentation and significant accounting policies
The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10-Q and Article 6 or 10 of Regulation S-X (“Regulation S-X”) under the Securities Act of 1933, as amended (the “Securities Act”). In the opinion of management, the consolidated financial statements reflect all adjustments and reclassifications that are necessary for the fair presentation of financial results as of and for the periods presented. All intercompany balances and transactions have been eliminated. Certain prior period amounts have been reclassified to conform to the current period presentation. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the year. Therefore, the unaudited financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2014.
Principles of consolidation
As required under GAAP and Regulation S-X, the Company will generally consolidate its investment in a company that is an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Accordingly, the Company consolidated the results of the Company’s subsidiaries in its consolidated financial statements.
Use of estimates
In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.
Fair value
The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy as more fully described in Note 5. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that management believes market participants would use in pricing the financial instrument at the measurement date.
The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3.
See Note 5 for additional information regarding fair value.
Segments
The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and cleantech industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.
19 |
Horizon Technology Finance Corporation and Subsidiaries
Notes to Consolidated Financial Statements
Investments
Investments are recorded at fair value. The Company’s board of directors (the “Board”) determines the fair value of the Company’s portfolio investments. The Company has the intent to hold its debt investments for the foreseeable future or until maturity or payoff.
Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if the Company otherwise does not expect to receive interest and principal repayments, the debt investment is placed on non-accrual status and the recognition of interest income may be discontinued. Interest payments received on non-accrual debt investments may be recognized as income, on a cash basis, or applied to principal depending upon management’s judgment at the time the debt investment is placed on non-accrual status. As of March 31, 2015, there was one investment on non-accrual status with a cost of $2.0 million and a fair value of $2.0 million. For the three months ended March 31, 2015, the Company recognized as interest income payments of $0.1 million received from one portfolio company whose debt investment was on non-accrual status. As of December 31, 2014, there was one investment on non-accrual status with a cost of $2.4 million and a fair value of $2.3 million.
The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may also receive a non-refundable deposit earned upon the termination of a transaction. Debt investment origination fees, net of certain direct origination costs, are deferred and, along with unearned income, are amortized as a level-yield adjustment over the respective term of the debt investment. All other income is recognized when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status.
Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not expect the borrower to be able to pay all principal and interest due. The proportion of the Company’s income consisting of interest and fee income that resulted from the portion of ETPs not received in cash for the three months ended March 31, 2015 and 2014 was 7.4% and 9.7%, respectively.
In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are also recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments.
Realized gains or losses on the sale of investments, or upon the determination that an investment balance or portion thereof is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.
Debt issuance costs
Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. Debt issuance costs are recognized as assets and are amortized as interest expense over the term of the related debt financing. The unamortized balance of debt issuance costs as of March 31, 2015 and December 31, 2014, included in other assets, was $2.1 million and $2.4 million, respectively. The accumulated amortization balances as of March 31, 2015 and December 31, 2014 were $3.3 million and $3.0 million, respectively. The amortization expense for the three months ended March 31, 2015 and 2014 was $0.3 million and $0.5 million, respectively.
20 |
Horizon Technology Finance Corporation and Subsidiaries
Notes to Consolidated Financial Statements
Income taxes
As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid corporate-level U.S. federal income tax on the income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute to its stockholders at least 90% of investment company taxable income, as defined by the Code, for each tax year. The Company, among other things, has made and intends to continue to make the requisite distributions to its stockholders, which will generally relieve the Company from corporate-level U.S. federal income taxes. Accordingly, no provision for federal income tax has been recorded in the financial statements. Taxable income differs from net increase in net assets resulting from operations which can be temporary, meaning they will reverse in the future or be permanent. In accordance with Accounting Standards Codification 946-205-45-3, permanent tax differences, such as non-deductible excise taxes paid, are reclassified from distributions in excess of net investment income and net realized loss on investments to paid-in-capital. These permanent book-to-tax differences are reclassified on the consolidated statements of changes in net assets to reflect their tax character but have no impact on total net assets. For the three months ended March 31, 2015 the Company reclassified $1.0 million to paid-in capital from distributions in excess of net investment income of $0.9 million and net realized loss on investments of $0.1 million, which related to excise taxes paid in prior years.
Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and pay a 4% excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. For the three months ended March 31, 2015 and 2014, $0.01 million and $0.04 million, respectively, was recorded for U.S. federal excise tax.
The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority in accordance with Topic 740, as modified by Topic 946, of the Financial Accounting Standards Board’s (“FASB”), Accounting Standards Codification, as amended. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. The Company had no material uncertain tax positions at March 31, 2015 and December 31, 2014. The 2013, 2012 and 2011 tax years remain subject to examination by U.S. federal and state tax authorities.
Distributions
Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized long-term capital gains, if any, are distributed at least annually, although the Company may decide to retain such capital gains for investment.
The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions and other distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board authorizes, and the Company declares, a cash distribution, then stockholders who have not “opted out” of the dividend reinvestment plan will have their cash distributions automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash distribution. The Company may use newly issued shares to implement the plan (especially if the Company’s shares are trading at a premium to net asset value), or the Company may purchase shares in the open market to fulfill its obligations under the plan.
21 |
Horizon Technology Finance Corporation and Subsidiaries
Notes to Consolidated Financial Statements
Transfers of financial assets
Assets related to transactions that do not meet Accounting Standards Codification Topic 860 — Transfers and Servicing requirements for accounting sale treatment are reflected in the Company’s consolidated statements of assets and liabilities as investments. Those assets are owned by special purpose entities that are consolidated in the Company’s financial statements. The creditors of the special purpose entities have received security interests in such assets, and such assets are not intended to be available to the creditors of the Company (or any other affiliate of the Company).
Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when (1) the assets have been isolated from the Company — put presumptively beyond the reach of the transferor and its creditors, even in bankruptcy or other receivership, (2) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets and (3) the transferor does not maintain effective control over the transferred assets through either (a) an agreement that both entitles and obligates the transferor to repurchase or redeem the assets before maturity or (b) the ability to unilaterally cause the holder to return specific assets, other than through a cleanup call.
New accounting pronouncements
In June 2013, the FASB issued Accounting Standards Update 2013-08, Financial Services — Investment Companies (Topic 946): Amendments to the Scope, Measurement and Disclosure Requirements, or ASU 2013-08, containing new guidance on assessing whether an entity is an investment company, requiring non-controlling ownership interest in investment companies to be measured at fair value and requiring certain additional disclosures. This guidance is effective for annual and interim periods beginning on or after December 15, 2013. ASU 2013-08 did not have a material impact on the Company’s consolidated financial position or disclosures.
In April 2015, the FASB issued Accounting Standards Update 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs, or ASU 2015-03, containing new guidance that will require debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. This guidance will be effective for annual and interim periods beginning on or after December 15, 2015. The Company is evaluating the impact ASU 2015-03 will have on the consolidated financial position and disclosures.
Note 3. Related party transactions
Investment Management Agreement
The Investment Management Agreement with the Advisor, which was amended and restated effective July 1, 2014, under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company was reapproved by the Board in August 2014. Under the terms of the Investment Management Agreement, the Advisor determines the composition of the Company’s investment portfolio, the nature and timing of the changes to the investment portfolio and the manner of implementing such changes; identifies, evaluates and negotiates the structure of the investments the Company makes (including performing due diligence on the Company’s prospective portfolio companies); and closes, monitors and administers the investments the Company makes, including the exercise of any voting or consent rights.
The Advisor’s services under the Investment Management Agreement are not exclusive to the Company, and the Advisor is free to furnish similar services to other entities so long as its services to the Company are not impaired. The Advisor is a registered investment adviser with the U.S. Securities and Exchange Commission. The Advisor receives fees for providing services to the Company under the Investment Management Agreement, consisting of two components, a base management fee and an incentive fee.
The base management fee under the Investment Management Agreement through and including June 30, 2014 was calculated at an annual rate of 2.00% of the Company’s gross assets, payable monthly in arrears. As a result of an amendment and restatement of the Investment Management Agreement, the base management fee on and after July 1, 2014 is calculated at an annual rate of 2.00% of (i) the Company’s gross assets, less (ii) assets consisting of cash and cash equivalents, and is payable monthly in arrears. For purposes of calculating the base management fee, the term “gross assets” includes any assets acquired with the proceeds of leverage. In addition, the Advisor has agreed to waive its base management fee relating to the proceeds raised in the public offering of the Company’s common stock that closed on March 24, 2015, to the extent such fee is not otherwise waived and regardless of the application of the proceeds raised, until the earlier to occur of (i) March 31, 2016 or (ii) the last day of the second consecutive calendar quarter in which the Company’s net investment income exceeds distributions declared on its shares of common stock for the applicable quarter. During the three months ended March 31, 2015, the Advisor did not waive base management fees.
22 |
Horizon Technology Finance Corporation and Subsidiaries
Notes to Consolidated Financial Statements
During the three months ended March 31, 2014, the Advisor waived base management fees of $0.1 million, which the Advisor would have otherwise earned on cash held by the Company at the time of calculation. The base management fee payable at March 31, 2015 and December 31, 2014 was $0.4 million. After giving effect of the waiver for the three months ended March 31, 2014, the base management fee expense was $1.0 million and $1.2 million for the three months ended March 31, 2015 and 2014, respectively.
The incentive fee has two parts, as follows:
The first part, which is subject to the Incentive Fee Cap and Deferral Mechanism, as defined below, is calculated and payable quarterly in arrears based on the Company’s pre-incentive fee net investment income for the immediately preceding calendar quarter. For this purpose, “Pre-Incentive Fee Net Investment Income” means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees received from portfolio companies) accrued during the calendar quarter, minus expenses for the quarter (including the base management fee, expenses payable under the Administration Agreement (as defined below), and any interest expense and any dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-Incentive Fee Net Investment Income includes, in the case of investments with a deferred interest feature (such as original issue discount, debt instruments with payment-in-kind interest and zero coupon securities), accrued income the Company has not yet received in cash. The incentive fee with respect to the Pre-Incentive Fee Net Investment Income is 20.00% of the amount, if any, by which the Pre-Incentive Fee Net Investment Income for the immediately preceding calendar quarter exceeds a 1.75% (which is 7.00% annualized) hurdle rate and a “catch-up” provision measured as of the end of each calendar quarter. Under this provision, in any calendar quarter, the Advisor receives no incentive fee until the Pre-Incentive Fee Net Investment Income equals the hurdle rate of 1.75%, but then receives, as a “catch-up,” 100.00% of the Pre-Incentive Fee Net Investment Income with respect to that portion of such Pre-Incentive Fee Net Investment Income, if any, that exceeds the hurdle rate but is less than 2.1875%. The effect of this “catch-up” provision is that, if Pre-Incentive Fee Net Investment Income exceeds 2.1875% in any calendar quarter, the Advisor will receive 20.00% of the Pre-Incentive Fee Net Investment Income as if the hurdle rate did not apply.
Pre-Incentive Fee Net Investment Income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. Because of the structure of the incentive fee, it is possible that the Company may pay an incentive fee in a quarter in which the Company incurs a loss. For example, if the Company receives Pre-Incentive Fee Net Investment Income in excess of the quarterly minimum hurdle rate, the Company will pay the applicable incentive fee up to the Incentive Fee Cap, defined below, even if the Company has incurred a loss in that quarter due to realized and unrealized capital losses. The Company’s net investment income used to calculate this part of the incentive fee is also included in the amount of the Company’s gross assets used to calculate the 2.00% base management fee. These calculations are appropriately prorated for any period of less than three months and adjusted for any share issuances or repurchases during the current quarter.
23 |
Horizon Technology Finance Corporation and Subsidiaries
Notes to Consolidated Financial Statements
Commencing with the calendar quarter beginning July 1, 2014, the incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three years and will be expensed when incurred. For this purpose, the look-back period for the incentive fee based on Pre-Incentive Fee Net Investment Income (the “Incentive Fee Look-back Period”) commenced on July 1, 2014 and will increase by one quarter in length at the end of each of the 12 succeeding calendar quarters, after which time, the Incentive Fee Look-back Period will include the relevant calendar quarter and the 11 preceding full calendar quarters. Each quarterly incentive fee payable on Pre-Incentive Fee Net Investment Income is subject to a cap (the “Incentive Fee Cap”) and a deferral mechanism through which the Advisor may recoup a portion of such deferred incentive fees (collectively, the “Incentive Fee Cap and Deferral Mechanism”). The Incentive Fee Cap is equal to (a) 20.00% of Cumulative Pre-Incentive Fee Net Return (as defined below) during the Incentive Fee Look-back Period less (b) cumulative incentive fees of any kind paid to the Advisor during the Incentive Fee Look-back Period. To the extent the Incentive Fee Cap is zero or a negative value in any calendar quarter, the Company will not pay an incentive fee on Pre-Incentive Fee Net Investment Income to the Advisor in that quarter. To the extent that the payment of incentive fees on Pre-Incentive Fee Net Investment Income is limited by the Incentive Fee Cap, the payment of such fees will be deferred and paid in subsequent calendar quarters up to three years after their date of deferment, subject to certain limitations, which are set forth in the Investment Management Agreement. The Company only pays incentive fees on Pre-Incentive Fee Net Investment Income to the extent allowed by the Incentive Fee Cap and Deferral Mechanism. “Cumulative Pre-Incentive Fee Net Return” during any Incentive Fee Look-back Period means the sum of (a) Pre-Incentive Fee Net Investment Income and the base management fee for each calendar quarter during the Incentive Fee Look-back Period and (b) the sum of cumulative realized capital gains and losses, cumulative unrealized capital appreciation and cumulative unrealized capital depreciation during the applicable Incentive Fee Look-back Period. As of March 31, 2015 and December 31, 2014, the quarterly incentive fee payable on Pre-Incentive Fee Net Investment Income was not limited by the Incentive Fee Cap and Deferral Mechanism.
The second part of the incentive fee is determined and payable in arrears as of the end of each calendar year (or, upon termination of the Investment Management Agreement, as of the termination date), and equals 20.00% of the Company’s realized capital gains, if any, on a cumulative basis from the date of the election to be a BDC through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis through the end of such year, less all previous amounts paid in respect of the capital gain incentive fee. However, in accordance with GAAP, the Company is required to include the aggregate unrealized capital appreciation on investments in the calculation and accrue a capital gain incentive fee on a quarterly basis, as if such unrealized capital appreciation were realized, even though such unrealized capital appreciation is not permitted to be considered in calculating the fee actually payable under the Investment Management Agreement.
During the three months ended March 31, 2014, the Advisor waived performance based incentive fees of $0.1 million which the Advisor would have otherwise earned. After giving effect of the waiver for the three months ended March 31, 2014, the performance based incentive fee expense was $0.7 million and $0.4 million for the three months ended March 31, 2015 and 2014, respectively. The performance based incentive fee payable as of March 31, 2015 and December 31, 2014 were $0.7 million and $0.8 million, respectively. The entire incentive fee payable as of March 31, 2015 and December 31, 2014 represented part one of the incentive fee.
Administration Agreement
The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s chief compliance officer and chief financial officer and their respective staffs. The administrative fee expense was $0.3 million and $0.2 million for the three months ended March 31, 2015 and 2014, respectively.
24 |
Horizon Technology Finance Corporation and Subsidiaries
Notes to Consolidated Financial Statements
Note 4. Investments
The following table shows the Company’s investments, all of which are with portfolio companies organized under the laws of the United States:
March 31, 2015 | December 31, 2014 | |||||||||||||||
Cost | Fair Value | Cost | Fair Value | |||||||||||||
(In thousands) | ||||||||||||||||
Money market funds | $ | 399 | $ | 399 | $ | 27 | $ | 27 | ||||||||
Restricted investments in money market funds | $ | 2,351 | $ | 2,351 | $ | 2,906 | $ | 2,906 | ||||||||
Non-affiliate investments | ||||||||||||||||
Debt | $ | 197,776 | $ | 197,610 | $ | 199,564 | $ | 199,180 | ||||||||
Warrants | 4,740 | 5,184 | 4,815 | 4,603 | ||||||||||||
Other Investments | 4,512 | 300 | 4,582 | 300 | ||||||||||||
Equity | 877 | 1,206 | 877 | 1,018 | ||||||||||||
Total non-affiliate investments | $ | 207,905 | $ | 204,300 | $ | 209,838 | $ | 205,101 |
The following table shows the Company’s portfolio investments by industry sector:
March 31, 2015 | December 31, 2014 | |||||||||||||||
Cost | Fair Value | Cost | Fair Value | |||||||||||||
(In thousands) | ||||||||||||||||
Life Science | ||||||||||||||||
Biotechnology | $ | 21,321 | $ | 22,221 | $ | 22,203 | $ | 22,586 | ||||||||
Medical Device | 27,794 | 27,246 | 23,129 | 22,462 | ||||||||||||
Technology | ||||||||||||||||
Communications | 18,220 | 17,802 | 18,392 | 17,973 | ||||||||||||
Consumer-Related | 6,565 | 7,291 | 6,556 | 7,228 | ||||||||||||
Data Storage | 4,535 | 318 | 4,604 | 318 | ||||||||||||
Internet and Media | 79 | 187 | 79 | 188 | ||||||||||||
Networking | 996 | 959 | 1,045 | 1,038 | ||||||||||||
Power Management | 7 | 55 | 7 | 56 | ||||||||||||
Semiconductors | 29,719 | 29,575 | 30,948 | 30,824 | ||||||||||||
Software | 61,034 | 61,620 | 54,482 | 54,905 | ||||||||||||
Cleantech | ||||||||||||||||
Alternative Energy | 6,999 | 6,971 | 8,283 | 8,076 | ||||||||||||
Consumer-Related | 161 | 161 | 396 | 396 | ||||||||||||
Energy Efficiency | 4,059 | 4,063 | 4,557 | 4,487 | ||||||||||||
Healthcare Information and Services | ||||||||||||||||
Diagnostics | 8,555 | 7,838 | 18,593 | 17,841 | ||||||||||||
Other | 8,449 | 8,468 | 7,157 | 7,201 | ||||||||||||
Software | 9,412 | 9,525 | 9,407 | 9,522 | ||||||||||||
Total non-affiliate investments | $ | 207,905 | $ | 204,300 | $ | 209,838 | $ | 205,101 |
Note 5. Fair value
The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no quoted market prices for certain assets or liabilities. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. Accordingly, the fair value estimates may not be realized in an immediate settlement of the asset or liability.
25 |
Horizon Technology Finance Corporation and Subsidiaries
Notes to Consolidated Financial Statements
Fair value measurements focus on exit prices in an orderly transaction (that is, not a forced liquidation or distressed sale) between market participants at the measurement date under current market conditions. If there has been a significant decrease in the volume and level of activity for the asset or liability, a change in valuation technique or the use of multiple valuation techniques may be appropriate. In such instances, determining the price at which willing market participants would transact at the measurement date under current market conditions depends on the facts and circumstances and requires the use of significant judgment.
The Company’s fair value measurements are classified into a fair value hierarchy based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The three categories within the hierarchy are as follows:
Level 1 Quoted prices in active markets for identical assets and liabilities.
Level 2 Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities in active markets, quoted prices in markets that are not active, and model-based valuation techniques for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.
Investments are valued at fair value as determined in good faith by the Board, based on input of management, the audit committee and independent valuation firms which are engaged at the direction of the Board to assist in the valuation of each portfolio investment lacking a readily available market quotation at least once during a trailing twelve-month period under a valuation policy and a consistently applied valuation process. This valuation process is conducted at the end of each fiscal quarter, with 25% (based on fair value) of the Company’s valuation of portfolio companies lacking readily available market quotations subject to review by an independent valuation firm.
Because there is not a readily available market value for most of the investments in its portfolio, the Company values substantially all of its portfolio investments at fair value as determined in good faith by the Board, as described herein. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company's investments may fluctuate from period to period. Additionally, the fair value of the Company's investments may differ significantly from the values that would have been used had a ready market existed for such investments and may differ materially from the values that the Company may ultimately realize. Further, such investments are generally subject to legal and other restrictions on resale or otherwise are less liquid than publicly traded securities. If the Company was required to liquidate a portfolio investment in a forced or liquidation sale, the Company could realize significantly less than the value at which the Company has recorded such portfolio investment.
Cash and interest receivable: The carrying amount is a reasonable estimate of fair value. These financial instruments are not recorded at fair value on a recurring basis and are categorized as Level 1 within the fair value hierarchy described above.
Money market funds: The carrying amounts are valued at their net asset value as of the close of business on the day of valuation. These financial instruments are recorded at fair value on a recurring basis and are categorized as Level 2 within the fair value hierarchy described above as these funds can be redeemed daily.
Debt investments: For variable rate debt investments which re-price frequently and have no significant change in credit risk, carrying values are a reasonable estimate of fair values. The fair value of fixed rate debt investments is estimated by discounting the expected future cash flows using the period end rates at which similar debt investments would be made to borrowers with similar credit ratings and for the same remaining maturities. At March 31, 2015 and December 31, 2014, the hypothetical market yield used ranged from 9% to 18%. Significant increases (decreases) in this unobservable input would result in a significantly lower (higher) fair value measurement. These assets are recorded at fair value on a recurring basis and are categorized as Level 3 within the fair value hierarchy described above.
26 |
Horizon Technology Finance Corporation and Subsidiaries
Notes to Consolidated Financial Statements
Under certain circumstances, the Company may use an alternative technique to value debt investments that better reflects its fair value such as the use of multiple probability weighted cash flow models when the expected future cash flows contain elements of variability.
Warrant investments: The Company values its warrants using the Black-Scholes valuation model incorporating the following material assumptions:
• | Underlying asset value of the issuer is estimated based on information available, including any information regarding the most recent rounds of borrower funding. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. |
• | Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on indices of publicly traded companies similar in nature to the underlying company issuing the warrant. A total of seven such indices are used. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. |
• | The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant. |
• | Other adjustments, including a marketability discount on private company warrants, are estimated based on management’s judgment about the general industry environment. |
• | Historical portfolio experience on cancellations and exercises of the Company’s warrants are utilized as the basis for determining the estimated time to exit of the warrants in each financial reporting period. Warrants may be exercised in the event of acquisitions, mergers or IPOs, and cancelled due to events such as bankruptcies, restructuring activities or additional financings. These events cause the expected remaining life assumption to be shorter than the contractual term of the warrants. Significant increases (decreases) in this unobservable input would result in significantly higher (lower) fair value measurement. |
Under certain circumstances the Company may use an alternative technique to value warrants that better reflects the warrants’ fair value, such as an expected settlement of a warrant in the near term or a model that incorporates a put feature associated with the warrant. The fair value may be determined based on the expected proceeds to be received from such settlement or based on the net present value of the expected proceeds from the put option.
The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 within the fair value hierarchy described above. The fair value of the Company’s warrants held in private companies is determined using both observable and unobservable inputs and represents management’s best estimate of what market participants would use in pricing the warrants at the measurement date. Therefore, the Company has categorized these warrants as Level 3 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.
Equity investments: The fair value of an equity investment in a privately held company is initially the face value of the amount invested. The Company adjusts the fair value of equity investments in private companies upon the completion of a new third-party round of equity financing. The Company may make adjustments to fair value, absent a new equity financing event, based upon positive or negative changes in a portfolio company’s financial or operational performance. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. The Company has categorized these equity investments as Level 3 within the fair value hierarchy described above. The fair value of an equity investment in a publicly traded company is based upon the closing public share price on the date of measurement. Therefore, the Company has categorized these equity investments as Level 1 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.
27 |
Horizon Technology Finance Corporation and Subsidiaries
Notes to Consolidated Financial Statements
Other investments: Other investments will be valued based on the facts and circumstances of the underlying agreement. The Company currently values one contractual agreement using a multiple probability weighted cash flow model as the contractual future cash flows contain elements of variability. Significant changes in the estimated cash flows and probability weightings would result in a significantly higher or lower fair value measurement. The Company has categorized this other investment as Level 3 within the fair value hierarchy described above. This asset is recorded at fair value on a recurring basis.
The following tables provide a summary of quantitative information about the Company’s Level 3 fair value measurements of its investments as of March 31, 2015 and December 31, 2014. In addition to the techniques and inputs noted in the table below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining its fair value measurements.
The following table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements as of March 31, 2015:
March 31, 2015 | ||||||||||||||||
Fair | Valuation Techniques/ | Unobservable | Weighted | |||||||||||||
Investment Type | Value | Methodologies | Input | Range | Average | |||||||||||
(In thousands, except share data) | ||||||||||||||||
Debt investments | $ | 192,563 | Discounted Expected Future Cash Flows | Hypothetical Market Yield | 9% – 18% | 11 | % | |||||||||
5,047 | Multiple Probability Weighted Cash | Probability Weighting | 10% – 65% | 33 | % | |||||||||||
Flow Model | ||||||||||||||||
Warrant investments | 4,264 | Black-Scholes Valuation Model | Price per share | $0.00 – $63.98 | $ | 3.39 | ||||||||||
Average Industry Volatility | 18% | 18 | % | |||||||||||||
Marketability Discount | 20% | 20 | % | |||||||||||||
Estimated Time to Exit | 1 to 5 years | 3 years | ||||||||||||||
Other investments | 300 | Multiple Probability Weighted Cash Flow Model | Discount Rate | 25% | 25 | % | ||||||||||
Probability Weighting | 100% | 100 | % | |||||||||||||
Equity investments | 222 | Market Comparable Companies | Price Per Share | $ 0.58 | $ | 0.58 | ||||||||||
Total Level 3 investments | $ | 202,396 |
The following table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements as of December 31, 2014:
December 31, 2014 | ||||||||||||||||
Fair | Valuation Techniques/ | Unobservable | Weighted | |||||||||||||
Investment Type | Value | Methodologies | Input | Range | Average | |||||||||||
(In thousands, except share data) | ||||||||||||||||
Debt investments | $ | 193,937 | Discounted Expected Future Cash Flows | Hypothetical Market Yield | 9% – 18% | 11 | % | |||||||||
5,243 | Multiple Probability Weighted Cash | Probability Weighting | 10% – 65% | 33 | % | |||||||||||
Flow Model | ||||||||||||||||
Warrant investments | 3,966 | Black-Scholes Valuation Model | Price per share | $0.04 – $63.98 | $ | 3.81 | ||||||||||
Average Industry Volatility | 18% | 18 | % | |||||||||||||